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ABSTRACT 
This dissertation sought to examine the metabolic syndrome (MetS) and its association 
with subclinical atherosclerosis, carotid artery remodeling and its related risk factors, as well as 
the longitudinal effect of MetS status changes on carotid artery remodeling, in midlife women in 
three manuscripts.   
In the first manuscript, the MetS, via all definitions, was significantly associated with 
measures of subclinical atherosclerosis. The MetS components most strongly and consistently 
associated with carotid IMT and plaque were higher blood pressure and greater fasting glucose 
across all definitions considered in the current study. 
In the second manuscript, the MetS was significantly associated with maladaptive 
remodeling of the common carotid artery. Our findings also showed that the association between 
MetS and carotid artery remodeling was independent of select measure of inflammatory, 
hemodynamic, and metabolic risk factors.  Finally, we observed differential maladaptive 
remodeling patterns of the common carotid artery with MetS status by race/ethnicity.   
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In the third manuscript, midlife women with persistent MetS status were observed to have 
maladaptive remodeling of the carotid artery compared to those who never developed MetS over 
time after adjusting for potential confounders. Higher systolic blood pressure and larger waist 
circumference were significant and consistent determinants of adverse carotid artery remodeling 
in our current study. 
Each manuscript contributes uniquely to public health.  Metabolic syndrome is associated 
with subclinical atherosclerosis in midlife women.  Pharmacological intervention and lifestyle 
changes to target and prevent the metabolic syndrome construct or its components among midlife 
women may subsequently slow or reduce progression of atherosclerosis. 
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 1.0  GENERAL INTRODUCTION 
 
1.1   EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE IN MIDLIFE 
WOMEN 
 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in women 
across all race and ethnic groups [1].   While the mortality rate due to CVD in the United States 
(US) over the last several decades has been declining, this rate of decline is slower for  women 
than  men [2]   In 2009, the overall rate of death attributable to CVD was 237.1 per 100,000 
persons.  Among women, the death rate for whites was 190.4 per 100,000, and 267.9 per 100,000 
for blacks [2]. 
While women experience almost as many CVD events as men,  events in women tend to 
occur at an older age [3].  The risk of death from CVD in women lags 10 years behind that of 
men, although the gap in incidence rates narrows after menopause [4]. Data from the Center for 
Disease Control and Prevention (CDC) indicate that the prevalence of modifiable risk factors 
among women have increased over the last decade. There are also racial and ethnic differences in 
both CVD events and their risk factors.  Rates of diabetes and obesity are on the rise and vary 
significantly by race and ethnicity.  Data show that  31.3% of white women, 53.2% of black 
women, and 41.8% of Mexican-American women are obese, which tracks with the incidence of 
diabetes of 8.2% in white women, 15.3% in black women, and 16.9% in Mexican-American 
women.  Black women have a 69% higher death rate from CVD compared to non-Hispanic white 
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women [5]. The disparity in CVD mortality rates by race and ethnicity appears to be in the 
prevalence of CVD risk factors [6].  There is also evidence of an age effect in the racial 
difference in CVD events, where greater disparities are found in younger age group [7].   
While CVD is not curable, per se, the modification of risk factors associated with the 
disease, such as  lifestyle changes including quitting smoking, engaging in physical activity and 
use of pharmacological intervention to target the risk factors of the CVD,  has lowered  CVD 
mortality rates in women by 23% since 2000 [8].  Traditional CVD risk factors in women 
include tobacco use, diabetes mellitus, hypertension, dyslipidemia, obesity, and an atherogenic 
diet.  Not surprisingly, these same factors are also associated or correlated with the metabolic 
syndrome (MetS). 
 
1.2 METABOLIC SYNDROME (MetS) CONSTRUCT 
 
1.2.1 History of the concept of metabolic syndrome 
 
The MetS was first described by Kylin, a Swedish physician, as a clustering of 
hypertension, hyperglycemia and gout [9].  Reaven reintroduced the concept via Syndrome X in 
1988 and proposed that insulin resistance is the main underlying component behind MetS [10].  
MetS is associated with a variety of other metabolic risk factors [11] and correlated with  many  
conventional cardiovascular risk factors [12].  It is important to point out that Reaven was 
putting forward a pathophysiological construct rather than a clinical or diagnostic tool, and much 
of the confusion about MetS has come about largely due to the lack of appreciation for this 
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distinction.  Interestingly, obesity was not one of the  core components put forth in Reaven’s 
seminal Syndrome X paper of 1988 [10]. 
Several publications have appeared since Reaven’s seminal paper; however, the exact 
pathophysiological mechanism underlying the MetS is still unknown.  The pathogenesis of MetS 
is suspected to be through the convergence of central obesity, physical inactivity, unhealthy diet 
and unknown genetic factors.  The etiology of MetS has been argued over for the last two 
decades, and as per Reaven’s proposition, some investigators suggest that the underlying 
pathophysiology of the MetS is insulin resistance, whereas others speculate that other metabolic 
risk factors may be involved as well [13].  Insulin resistance is clearly related to many of the 
components that define MetS, and several metabolic pathways are known to link insulin 
resistance to other risk factors such as central obesity [14, 15]. Visceral adiposity is thought to be 
a predominant etiological factor, and the theory suggests that metabolically active visceral 
adipose tissue releases fatty acids and a variety of adipokines, which are implicated in the 
development of  the insulin resistance state [16]. Low grade inflammation has also been 
postulated to play a role in development of MetS [17] and  is also linked to overall and visceral 
adiposity and insulin resistance.   
The terminology used to describe MetS has changed over the years. It used to be referred 
to as Syndrome X and the insulin resistance syndrome, among others.  Along with these name 
changes, many organizations have put forward their own definition of the MetS and the 
associated composition of factors characterizing the MetS. The goals of these organizations have 
guided their selection of criteria and cut-points that define the MetS. 
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1.3 DEFINITIONS OF METABOLIC SYNDROME 
 
Table 1-1 describes four commonly used definitions of MetS.  In 1998, the World Health 
Organization (WHO) was the first organization to define specific criteria in identifying people 
with MetS  [18].  The WHO criteria included insulin resistance as the primary requirement in 
their definition.  According to the definition, individuals are required to be either (1) insulin 
resistant, (2) diagnosed with type 2 diabetes or (3) have impaired glucose tolerance. This 
requirement of insulin resistance has hampered the widespread use of the WHO criteria to 
categorize individuals with or without MetS.  Coupled with insulin resistance, the definition 
requires that individuals meet at least two of the following criteria:  obesity, dyslipidemia, 
hypertension and micro-albuminuria.  
To address the difficulty in using the WHO criteria, the European Group for the Study of 
Insulin Resistance (EGIR)  developed its own criteria in 1999 [19]. The goal of EGIR was to 
modify the WHO criteria and make it practical to use.  With respect to insulin resistance, EGIR 
proposed using fasting insulin as a measure or surrogate for insulin resistance.  In using this 
method to determine insulin resistance, individuals with type 2 diabetes are excluded from EGIR 
criteria because fasting insulin is not an appropriate method to measure insulin resistance in 
those with diabetes.  The technique to assess obesity was changed from hip-to-waist ratio to 
waist circumference. Furthermore, micro-albuminuria was excluded from their definition. 
The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP 
III) proposed an alternative clinical definition for MetS in 2001. The aim of NCEP  was to 
identify individuals at long-term risk for CVD, and who are likely to benefit from clinical 
intervention to mitigate the risk of CVD [17].  NCEP criteria placed equal importance on all 
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components of MetS as compared to other definitions, which placed a higher emphasis on 
glucose-related components.  With respect to abdominal obesity, the National Institutes of Health 
(NIH) obesity clinical guidelines were used to define the cut-off points for abdominal obesity in 
US adults.  A joint effort by American Heart Association (AHA) and the National Heart Lung 
and Blood Institute (NHLBI) in 2005 led to an updated version of the NCEP criteria [17].  While 
the components of the definition were maintained, lower cut-off points were incorporated for the 
determination of elevated fasting glucose levels from greater 110 mg/dL to 100 mg/dL [17].  The 
NCEP definition is used frequently because it is practical and easy to ascertain the components.  
Following the publication of the NCEP-ATP III criteria, studies about the prevalence of 
MetS in different parts of the world have been published using varying definitions but the most 
commonly used definitions were NCEP-ATP III and WHO.   In all, the  prevalence of  MetS is 
similar but the concordance  across definitions is  relatively poor [18, 20]. In a response to this 
concern, the International Diabetes Federation (IDF) introduced a new definition for MetS in 
2005, which is similar to NCEP- ATP III definition, but with more emphasis on central obesity 
[21].  Furthermore, the cut-points for abdominal obesity are different based on ethnicity and 
nationality. 
Given the definitions of MetS from various organizations, questions regarding the ability 
of the different MetS criteria to predict morbidity and mortality outcomes remain (Table 1-2).   
The predictive ability of the varying MetS definitions is a major concern to many investigators. 
To address this concern, IDF and NCEP teamed up with other organizations to develop 
guidelines for a definition based on what has been learned to date [22] . The findings from this 
collaborative effort are (1) that no single component should be obligatory in the composition of 
the definition, and (2) that a single set of cut-off points should be used for all components with 
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the exception of waist circumference where population specific values are applied.  This 
collaboration reiterated that  three abnormal metabolic components out of 5 are required for the 
positive classification of  MetS [22]. 
The predictive capability of MetS in the classification of people at higher risk of incident 
CVD and diabetes remains an issue. Thus far, various definitions have shown different predictive 
values in assessing CVD risk. This raises the issue of developing a definition of MetS that is 
more robust in differentiating individuals at greater risk of CVD and diabetes. This difficulty 
might have led some to conclude, prematurely, that MetS is more of an educational concept than 
a diagnostic tool [23]. 
 
1.4 PATHOPHYSIOLOGY OF METABOLIC SYNDROME 
 
The pathophysiology of MetS is  unknown [16].  Many postulations regarding the 
evolution and mechanism of how MetS affects CVD risk and outcome have been suggested, but 
none has been accepted to be the primary culprit because many of the suspected mechanisms 
overlap (Figure 1), and it is difficult to tease them apart.   The school of thought of Reaven and 
Ferrannini suggests that insulin resistance is the central underlying mechanism of MetS.  This 
observation is based on the fact that insulin resistance is strongly associated with metabolic risk 
factors and correlated with CVD risk [10, 24].  Another highly suspected mechanism is central 
obesity, which is strongly associated with MetS [24].   Several other underlying mechanism 
include the release of free fatty acids from adipocytes [25], the chronic activation of the immune 
system [26], an altered glucocorticoid hormone activation [27] and,  the contribution of 
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cytokines, hormones and other molecules released by adipocytes [28].  Aging and lifestyle 
factors, such as diets rich in saturated fats and carbohydrates and physical inactivity are also 
associated with the development of MetS [29]. 
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Figure 1-1 Pathogenesis of Metabolic Syndrome  
Adapted from Grundy et al [30] 
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1.5 METABOLIC SYNDROME RISK FACTORS 
 
Cardiovascular risk factors tend to cluster in the same way as do many of the most 
common factors that determine the MetS. These risk factors chiefly include central obesity, 
insulin resistance, hyperglycemia, hypertension and dyslipidemia. These abnormalities are often 
interrelated, and tend to share similar underlying mediators, mechanisms, and pathways [17]. 
 
1.5.1 Insulin resistance and glucose intolerance 
 
             Insulin resistance (IR) is a physiological condition in which cells fail to respond to the 
normal actions of the hormone insulin [15].  IR  is widely considered the main factor initiating 
the biochemical processes underlying the metabolic syndrome [10].  Given this notion about 
MetS, the prevention and management of MetS have focused on controlling glucose and lipid 
levels to prevent damage to the vasculature.   Although the pathophysiology processes 
underlying MetS are unclear, experimental and epidemiological evidence support the insulin 
resistance theory [31].  A defect in insulin action hampers the ability of insulin to suppress 
glucose production by the liver, which in turn affects glucose uptake disposal and metabolism in 
skeletal muscle and adipose tissue [15].   Insulin sensitivity is assessed by both the number and 
the affinity of insulin receptors, as well as the functional state of the intracellular signaling 
pathways that convert insulin binding to the various effectors [11].  A decrease in the number of 
insulin receptors is associated with insulin resistance [32]. Insulin is a potent growth factor that 
stimulates growth-promoting effects mediated through the mitogen-activated protein (MAP) 
kinase pathway [33].  The stimulation of MAP kinase pathways tends to be inactive in 
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individuals with insulin resistance leading to smooth muscle cell proliferation, higher collagen 
formation and elevated production of growth factors, and inflammatory cytokines that may 
contribute to the development of atherosclerosis [34]. 
 
1.5.2 Central obesity 
 
Although obesity was not among the original Syndrome X risk factors postulated by 
Reaven,  the MetS and its components are strongly associated and correlated with measures of 
obesity, such as waist circumferences [35].  The explanation attributed to this association is that 
excess adiposity lowers insulin-mediated glucose disposal and raises the likelihood of insulin 
resistance [36].  However, the relationship between adiposity and insulin resistance is not simple 
or straightforward.  While weight per se is not a criterion for MetS, the distribution of fat and its 
location (visceral or subcutaneous) appears critical. Individuals with MetS tend to have an 
abnormal fat distribution with a  high concentration of fat located centrally [17].  Both the 
accumulation of fat in a visceral location and in the upper body are highly correlated with insulin 
resistance [37].   
 
In this context, body fat distribution, such as visceral adipose tissue accumulation, has 
been found to  correlate significantly with metabolic abnormalities [38].  Waist circumference 
has been shown  to explain more obesity related health risks compared to BMI [39].  However, 
others have reported that waist circumference provides additional information over BMI with 
respect to the risk of CVD and type 2 diabetes [40, 41].  Waist circumference and BMI, both 
indices of adiposity, are highly correlated and their predictive capabilities appear to be similar 
[42].   
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Abdominal obesity is one of the key components of MetS, and the overall tissue fat 
accumulation leading to lipotoxicity is a major cause of insulin resistance and beta-cell 
dysfunction and may contribute to accelerated atherosclerosis [43].   Insulin resistance leads to 
the increased delivery of free fatty acids (FFA) from adipose tissue and decreased FFA uptake by 
the muscles, resulting in elevated FFA influx to the liver [44].  In humans, there is a correlation 
between visceral fat accumulation and transportation of nonesterified fatty acids (NEFA) to the 
liver, and this raises the possibility that  other factors  are  at play that could explain the altered 
metabolic profile of viscerally obese individuals [45]. Given that the metabolic syndrome is often 
found among people with visceral obesity, Despres et al argued that altered NEFA metabolism 
and endocrine function show that visceral adipose tissue is causally involved in the 
pathophysiology of MetS[46].   
 
1.5.3 Hypertension 
  
Elevated blood pressure, a risk factor for CVD, is included as a component of metabolic 
syndrome in all guidelines that define the construct.  Although, some investigators have been 
reluctant to associate BP with MetS because analyses of the individual components of MetS have 
shown a weak association between hypertension and other components of MetS [47].  The  
association between elevated blood pressure  and MetS is strongly correlated via  obesity, and 
nearly  half of individuals with hypertension or who are obese also have MetS [48].  Moreover, 
the link between insulin resistance and hypertension is  well established, and it is connected via 
several different mechanisms [49].  Compensatory hyperinsulinemia in insulin resistance may 
cause elevated blood pressure by increasing sympathetic nervous system activation [50], and 
stimulation of vascular smooth muscle cell growth [51].  
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 1.5.4 Dyslipidemia 
 
Dyslipidemia is an integral component of metabolic syndrome, and a key contributor to 
higher cardiovascular risk in individuals with MetS.  Low levels of high density lipoprotein 
HDL-cholesterol (HDL-c), elevated triglycerides and high levels of small, dense low density 
lipoprotein-cholesterol (LDL-c) molecules are the main lipid abnormalities used in definitions of 
MetS [52].  
 
The processes that are thought to initiate dyslipidemia in individuals with MetS are 
known to start from insulin resistance at the level of adipose tissue [16]. This leads to increase in 
the release and a decrease in the clearance of FFAs.  Adipocytes release FFA into the portal 
venous system and are taken up by the liver in proportion to their circulating concentration [53].  
Among individuals with insulin resistance, the inhibition of FFA released from adipocytes is 
impaired, leading to higher levels of apolipoprotein B (Apo B), regulated at the posttranslational 
stage by the availability of lipids for synthesis of very low-density lipoprotein (VLDL) particles 
[54]. An increase in VLDL concentration could also result from a decrease in degradation or  
suppression of microsomal triglyceride transfer protein activity, which is the key component of 
the VLDL-assembly process [55].  The cholesterol ester transfer protein (CETP) and hepatic 
lipase are associated with the generation of low HDL levels and small, dense LDL[56].   
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1.6 OTHER RISK FACTORS OF METABOLIC SYNDROME 
 
1.6.1 Risk factors associated with lifestyle 
 
The epidemic of sedentary lifestyle and obesity has public health and economic 
consequences.  Physical inactivity is associated with incident stroke, obesity, type 2 diabetes, 
insulin resistance, hypertension and other adverse conditions [57].  Furthermore, a sedentary 
lifestyle is also an independent risk factor for the development of MetS [58]. Yang et al observed 
that being physically active delayed or prevented the incidence of MetS [59]. 
 
The relationship between diet and development of MetS, however, has not been fully 
established.  A recent systematic review by Crichton et al found that dairy consumption has a 
beneficial effect on the development of MetS.  Seven of  thirteen studies found that dairy intake 
was inversely associated with incident or prevalent MetS [60]. Consumption of whole-grains is 
inversely associated with MetS, whereas the consumption of refined-grains is positively 
associated with MetS [61].  A population - based cohort study conducted in Finland among 
middle-aged participants found that a reduction in sodium intake had a significant positive effect 
on the treatment of people with MetS via  reduction in blood pressure [62]. 
 
The relationship between alcohol consumption and MetS is controversial.  A cross-
sectional analysis of data from 8,125 participants from National Health and Nutrition 
Examination Survey (NHANES) showed that mild to moderate alcohol consumption was 
associated with a lower prevalence of MetS.  A beneficial effect of alcohol consumption was also 
found for lipids, waist circumference and fasting insulin [63].  Again, in using the 1999-2002 
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NHANES data to study the pattern of alcohol consumption and MetS, Fan et al observed that 
drinking in excess of dietary guidelines was associated with a greater  prevalence of impaired 
fasting glucose or diabetes mellitus, hypertriglyceridemia, abdominal obesity and high blood 
pressure [64].  A prospective study conducted in Korea showed that heavy drinking was 
associated with a higher risk of developing MetS through its influence on the individual MetS 
components.  Although, the risk of association varied with respect to the type of alcohol 
consumed [65].   In a large study conducted in Korea that assessed the association between 
alcohol consumption and the MetS, alcohol consumption was found to have a significant inverse 
association with low HDL-c. Also, there was dose-response relationship between alcohol 
consumption and the incidence of MetS, and  the authors postulated that this finding might have 
been  the result of the effect of alcohol on other components of MetS [66]. 
 
1.6.2 Genetics of metabolic syndrome 
 
Genetics are suspected to play a role in the development of MetS and its individual 
components.  Family and twin studies have shown that MetS and its components tend to cluster 
among families, especially among twins [67].   In a study of 2,508 male twin pairs, concordance 
for the clustering of three MetS components – diabetes, obesity and hypertension - was found in 
31.6% for monozygotic pairs versus 6.7% for dizygotic pairs. [68]. A number of studies have 
sought to identify an underlying genetic link but to date no particular gene has emerged as a 
potential candidate [69]. In light of these efforts, some investigators have argued that there is  no 
genetic basis for incident  MetS [69]. In a genome-wide association study, no significant finding 
between MetS and candidate genes was observed, which lends some supports the notion that 
there is no genetic basis in the development of MetS [70]. 
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 1.7 CLINICAL OUTCOMES OF METABOLIC SYNDROME 
 
Several prospective studies have reported an association between MetS and both incident 
CVD (Table 2) [71, 72], and type 2 diabetes mellitus [73].  Furthermore, people with MetS are 
prone to other co-morbid conditions, such as obstructive sleep apnea [74], gallstones [75], 
asthma, fatty liver disease, insulin resistance and polycystic ovarian syndrome in women [76]. 
MetS is a strong predictor of incident CVD events. In a systematic review of 
cardiovascular risk associated with the MetS as defined by the 2001 NCEP and the 2004 revised 
NCEP definition, MetS was observed to be associated with a 2-fold higher risk in CVD mortality 
and a 1.5 fold higher risk for all-cause mortality [71].  Findings from several studies have 
confirmed that CVD morbidity, mortality, and all-cause mortality are higher among individuals 
with MetS [71, 72]. In an NHANES III study, MetS was associated with prevalent myocardial 
infarctions and strokes [77].  In the Botnia study,  Isomaa et al showed that  middle-aged adults 
with MetS have a  nearly a 3-fold higher risk of incident coronary heart disease, and more than a 
2-fold higher  risk for  stroke [78].  There is also sex differential  effect with CVD-risk related to 
MetS being one-third higher in women compared to men [12]. 
MetS is also a strong predictor of incident type 2 diabetes mellitus [12].  Several 
epidemiological studies put the risk of incident type 2 diabetes among people with MetS around 
2 to 5-fold higher compared to those without MetS[79]. Several of the components of MetS 
appear to be more strongly associated with the development of type 2 diabetes.  As expected, the 
evidence suggests that impaired fasting glucose is the component most strongly associated  with 
incident type 2 diabetes [80].  Other studies have shown that both abdominal obesity and 
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hyperglycemia are  strongly associated with incident type 2 diabetes [81].  Other studies have 
reported that MetS in and of itself is not predictive of type 2 diabetes when its individual 
components are also considered [82].  However, in  the San Antonio Heart study, MetS was 
associated with incident type 2 diabetes  independent of  other CVD risk factors such as sex, age, 
race, family history of type 2 diabetes, fasting insulin and impaired glucose tolerance [83]. 
MetS in women is associated with higher risk of CVD as compared to men.  Gami et al  
showed  that CVD risk associated with MetS was  one-third higher in women than in men [12]. 
However, the reasons for this disparity are not clearly understood.  It has been postulated that 
central obesity, which is  more prevalent among women than men independent of age, maybe the 
reason for higher CVD risk among women [84].  It has also been suggested that changes that 
occur in women during the menopausal transition, such as a decrease in HDL-c, or an increase in 
both LDL, and the smaller and more dense VLDL particles, put women at a higher risk of CVD 
compared to men (Blake, Otvos et al. 2002).   The fact that MetS in women predicts the 
incidence of both type 2 diabetes and CVD is not surprising given the fact that the individual 
components of MetS are also known risk factors for CVD and type 2 diabetes.  Moreover, MetS 
and its components are associated with the early markers of atherosclerosis [85]. 
 
1.8 TREATMENT OF METABOLIC SYNDROME 
 
Given that MetS syndrome is associated with a higher risk for the development of  type 2 
diabetes and CVD [71], it is important to treat individuals with this phenotype to lower their risk 
or delay the onset of clinical outcomes. The clinical significance, however, of MetS is 
controversial. Nonetheless, it is critical to identify individuals with MetS so that effective and 
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early treatment can be initiated to mitigate the effects of MetS, and reduce the incidence of 
disease associated with it.  Lifestyle modifications including, a healthy diet, physical activity, 
cessation of smoking and weight control/loss, and pharmacological intervention targeting 
specific MetS components are the main treatment options in the management of metabolic 
syndrome [86]. 
 
1.8.1 Lifestyle modifications 
 
Engaging in behaviors that help to encourage weight loss are first-line treatments for 
MetS [86]. Weight loss has been found to be effective in treating obesity, hypertension, insulin 
resistance and the other components of MetS. Even a small amount of weight loss can have a 
significant impact in lowering triglycerides and subsequently increasing HDL-cholesterol [17].  
In the Finnish Diabetes Prevention study, the lifestyle intervention alone, consisting of 
individualized counseling, physical activity and increasing intake of fiber, was associated with a 
reduction in  abdominal obesity and the  overall prevalence of MetS in the long term [86]. 
 
Dietary intake has been shown to have a significant impact on the resolution of MetS and 
its components. Besides weight loss and  a restriction in caloric intake, a diet high in unsaturated 
fats and complex carbohydrates and low in sodium, is recommended to be followed  by  
individuals with MetS   to reduce and/or maintain weight.[17].  Consumption of foods low in 
carbohydrates tends to have a favorable effect on the MetS and serum lipid profiles.  However, 
the value  of  low carbohydrate diets in the long term have been questioned because they are 
difficult to maintain [87].  
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Regular exercise has also been shown to influence MetS and its components, but it is not 
known if exercise can prevent or treat MetS [88].  Middle-aged Finnish men who engaged in 
moderate or high-intensity leisure-time physical activity at least 3 hours / week were half as 
likely as sedentary men to develop MetS during the 4 year follow-up period [88].  Also, 
participation in resistance type exercises improved MetS status among adults with impaired 
glucose tolerance [89].  Furthermore, long-term physical activity, without weight loss, may 
potentially prevent  MetS [90].  
 
1.8.2 Pharmacological intervention 
 
Individuals with MetS stand to benefit from pharmacologic approaches to modify CVD 
risk factors.  It must be pointed out that there is no specific pharmacological intervention for 
individuals with MetS.  The current treatment guidelines specify that the focus of treatment must 
target the individual risk factors separately with one or multiple drugs, if necessary [52]. 
 
1.9 CRITICISM AND LIMITATIONS OF METABOLIC SYNDROME 
CONSTRUCT 
 
The concept of MetS has been criticized on the basis of its pathophysiological 
underpinning as well as the clinical utility of the construct [31]. A number of organizations have 
proposed different definitions for the MetS concept with various emphases on risk factors for 
CVD and type 2 diabetes.  The emphases on various risk factors, however, may have created 
confusion about the usefulness of MetS in clinical practice. This has led some investigators to 
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question the essence of MetS because the etiology is unknown [31]. The pathogenesis of MetS is 
suspected to be multifactorial. Hanley et al have demonstrated that metabolic abnormalities 
cluster together to a greater extent than would be expected by chance alone [91].    There are 
questions with respect to the risk associated with having the MetS construct and the individual 
components of the MetS. However, MetS has been associated with higher CVD events and the 
development of diabetes [12].  On the contrary, other studies have also shown that MetS does not 
predict CVD risk beyond the additive effects of the individual MetS components [92].  In the 
same vein,  several studies have reported that fasting glucose alone is a good, if not better 
predictor, of type 2 diabetes than MetS [82]. With respect to predicting CVD risk, MetS did not 
perform any better than the Framingham Risk Score (FRS) [93]. However, Sipila et al have 
shown that MetS is a significant predictor of CVD after adjusting for the FRS [94]. 
The definition of MetS and its individual components have been recalibrated periodically 
given the debates that have stymied its usefulness in a clinical setting.  The nature of the binary 
construct of MetS risk factors is also a source of debate among investigators.  Some have argued 
that using a binary variable to classify a set of risk factors could lead to information loss, and 
therefore the questions about the  predictive power of the MetS construct in discriminating  those  
at risk [95].  Given the extent of these concerns, a WHO expert consultation group issued a 
report on the utility of MetS concept in relation to  pathophysiology, epidemiology, clinical work 
and public health, while recognizing  the limited usefulness of the MetS construct as  a 
diagnostic or management tool [96].   
The risk of CVD and type 2 diabetes increases with an increasing number of MetS 
components [97] such that, an individual positive for all 5 MetS components would be expected 
to be at much greater risk of CVD and possibly type 2 diabetes than someone positive for 4 or 
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fewer individual components.  The effect of each of individual risk factors of MetS is likely not 
the same, and so  to treat them the same is problematic [95].   Moreover, it is important to 
recognize that the MetS construct does not account for or incorporate important CVD risk factors 
such as age, sex, smoking, family history and physical activity levels, all of which are associated 
with higher cardiovascular risk [76]. For MetS to be a putative risk factor for both CVD and type 
2 diabetes, all other possible confounding factors need to be controlled for in order to tease out 
the exact effect of the MetS construct on the risk for future CVD and diabetes events. 
 
1.10 EPIDEMIOLOGY OF METABOLIC SYNDROME IN MIDLIFE 
WOMEN 
 
The prevalence of MetS increases with age [98].  This observation has been made in all 
races and ethnic groups around the world with varying levels with regards to gender.   Using data 
from  (NHANES) III, Ford et al  found the overall prevalence of MetS in an adult population to 
be 24%, with the prevalence increasing from 6.7% among those 20-29 years of age to 43.3%  
among those 60-69 years of age [99].  Among US adults, no significant gender difference  was 
observed with respect to  prevalence of MetS (23.7 % in women and 24.0% in men) [99].  
Among racial and ethnic groups in the US, the highest prevalence of MetS was found in 
Hispanics (32%) as compared to Whites (22%) and Blacks (22%) [99].  In women, the 
prevalence was lower among Whites than among Blacks or Mexican American women [100]. 
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The epidemiology of MetS among midlife women varies depending on the definition that is used 
to characterize the prevalence.  In a study conducted in Sweden, the prevalence of the MetS 
varied with the definition used and ranged from 10 to 15% among midlife women [29].  In a 
Korean study, using NCEP-ATP III criteria, the age-adjusted prevalence of MetS in midlife 
women was 30.0%, nearly twice the levels found among men.  Furthermore, the findings also 
showed a rapid increase in the prevalence of MetS from the age of 50 through 59 [22].   In a 
cross-sectional study conducted in an urban Iranian city, the prevalence of MetS among middle 
aged women was 31% [43]. While there are a number of prevalence studies of the MetS 
spanning many countries across the world and incorporating various definitions of MetS, no 
study has evaluated different definitions of MetS in midlife women in the United States. 
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Table 1-1 Metabolic syndrome definitions 
WHO NCEP ATP III AHA/NHLBI IDF 
WHO requires a 
person to have type 2 
diabetes mellitus or 
impaired glucose 
tolerance 
 and ≥ 2 of the 
following: 
NCEP requires any 
three of the five 
criteria to be met 
AHA/NHLBI requires 
any three of the five 
criteria to be met 
 IDF  requires a person to have central obesity 
as defined by waist criterion below (with 
various ethnicity specification) and ≥ 2 of the 
following: 
Obesity Waist-hip ratio 
>0.90 in men 
>0.85 in women 
and/or BMI >30 kg/m2
Waist 
(≥ 102 cm or ≥ 40 
inches) in men  
( ≥ 88 cm  or ≥35 
inches) in women 
Waist 
(≥ 102 cm or ≥ 40 
inches) in men  
( ≥ 88 cm  or ≥35 
inches) in women 
Waist 
≥ 94 cm for European men 
≥ 80 cm in  European women; ethnicity-
specific values for other group 
Blood 
pressure 
≥ 140/90 mmHg or on 
antihypertensive 
medication 
≥130/85mmHg or on 
medication 
≥130/85mmHg or on 
medication 
≥130/85 mmHg or antihypertensive 
medication 
Triglycerides ≥150 mg/dL ≥150 mg/dL on 
triglycerides-lowering 
medication 
≥150 mg/dL on 
triglycerides-lowering 
medication 
>150 mg/dL or triglycerides-lowering 
medication 
HDL-
cholesterol 
<35 mg/dL in men 
<39 mg/dL in women 
< 40 mg/dL in men 
< 50 mg/dL in women 
or HDL-raising 
medication 
< 40 mg/dL in men 
< 50 mg/dL in women 
or HDL-raising 
medication 
<40 mg/dL in men 
<50 mg/dL in women 
or HDL-raising medication 
Fasting ≥110 mg/dL or on ≥100 mg/dL or on anti- ≥ 100  mg/dL or previously diagnosed type 2 
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WHO NCEP ATP III AHA/NHLBI IDF 
plasma 
glucose 
anti-diabetic therapy diabetic therapy diabetes 
Micro 
albuminuria 
Overnight urinary 
albumin excretion rate 
>20 mg/min 
 WHO, World Health Organization; NCEP, National Cholesterol Education Program; AHA/NHLBI, American Heart Association / National Heart, Lung, 
 and Blood Institute; IDF, International Diabetes Federation; *, Drug treatment is an alternative. 
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Table 1-2 Studies of the Metabolic Syndrome (MetS) Associated with the risk of Cardiovascular Disease 
Study Name and 
Author 
Study  
population 
Definition of 
MetS 
 Prevalence of 
the MetS at 
baseline 
Duration  of 
follow-up 
 Variables  
controlled  for in 
the study 
Endpoint or 
measurable 
outcome 
Results or 
findings 
Health ABC, 
Holvoet et 
al[101] 
3033 men and 
women aged 70-
79 years in the 
US 
 ATP III 38% Questionnaire 
every 6 months 
Sex, age, 
ethnicity, 
smoking 
CHD incidence MetS is a risk 
factor for CHD 
Framingham 
Offspring Study, 
Rutter et al[102] 
3037 men and 
women aged 26-
82. No history of
diabetes or family 
CVD 
ATP III 23.8% 7 years Age, sex CVD incidence MetS is 
independent 
predictor of  CVD 
events 
San Antonio 
Heart Study, Hunt 
et al[103] 
2815 men and 
women age 25-64 
years in the US 
ATP III 25.2% 12.7 years; 
Questionnaire, 
telephone 
interviews 
Age, sex, race CVD - all cause 
mortality 
MetS predictive 
of  CVD in the 
study 
ARIC Study, 
McNeill et 
al[104] 
12089 men and 
women aged 45-
64 years in US. 
Participants with 
diabetes and 
family history of 
CVD are 
excluded 
 ATP III 23.5% 11 years, Physical 
examination 
Race, age, site, 
smoking, LDL-
cholesterol 
CHD-Stroke 
incidences 
Participants with 
MetS were at 
increased risk of 
long term CVD 
outcome 
Botnia Study,  
Isomaa et al[78] 
4483 men and 
women age 35-70 
years in  Sweden 
and Finland 
WHO  Not available  Median follow-
up 6.9 
Age, Sex, 
smoking, LDL-
cholesterol 
CVD morbidity 
and mortality 
MetS identified 
participants with 
increased CVD 
morbidity and 
mortality 
Bruneck Study, 
Bonora et al[105] 
888 men and 
women aged 40-
79 years in Italy 
 WHO 34.1% 5 years Age, sex, 
smoking, alcohol, 
physical activity, 
history of CVD, 
LDL-cholesterol 
CHD incidence Participants with 
MetS are at 
increased risk for 
CHD 
British Women’s Women aged 60- IDF 48% 15778 woman- Age, smoking,  CVD- all-cause MetS is modestly 
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Study Name and 
Author 
Study  
population 
Definition of 
MetS 
 Prevalence of 
the MetS at 
baseline 
Duration  of 
follow-up 
 Variables  
controlled  for in 
the study 
Endpoint or 
measurable 
outcome 
Results or 
findings 
Heart and Health 
Study, Lawlor et 
al [106] 
79 years, free of  
CHD at baseline 
in United 
Kingdom 
years inactivity and 
life-course 
socioeconomic 
position 
mortality associated with 
CHD risk in older 
women 
 Kuopio Ischemic 
Heart Disease,  
Wang et al[107] 
1025 men and 
women aged 65-
74 years in 
Finland 
IDF  Not available 13.5 years Age, gender, 
tobacco, current  
smoking, 
consumption of 
alcohol and 
physical activity 
at leisure and 
total cholesterol 
CVD-mortality MetS is a marker 
of CVD risk 
The Malmo Diet 
and Cancer study 
, Nilsson et 
al[108] 
5047 men and 
women, middle-
aged, non-
diabetic 
participant in 
Sweden 
IDF/ ATP/EGIR 21.9% 11 years Age, gender, 
LDL-cholesterol, 
life-style factors 
CVD events IDF was not 
superior to ATP 
and EGIR for 
prediction  of 
event events 
CVD, Cardiovascular disease; CHD, Coronary Heart Disease; IDF, International diabetes Federation; WHO, World Health Organization;  ATP III, Adult Treatment 
Panel III; EGIR, European Group for the Study of Insulin Resistance; US, United States 
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Table 1-3  Studies of the Metabolic Syndrome (MetS) Associated with subclinical vascular measures 
Authors Study  Design Objective Study Population Subclinical 
CVD 
measures 
Metabolic 
syndrome 
(MetS) 
Results/Findings Strengths/Limitations 
Skilton et 
al[109] 
 Cross-sectional Examine the 
associations 
between early 
carotid 
atherosclerosis and 
MetS definitions 
Men and women 
participants at risk 
for CVD and 
dyslipidemia 
Carotid 
IMT; 
Carotid 
plaque 
IDF 
AHA/NHLBI 
NCEP-ATP 
III 
MetS independently  
associated with 
increased 
atherosclerosis 
supporting screening 
for MetS among 
people at risk of 
CVD 
Participants  were  at risk 
for CVD compared to 
the broader general 
French population 
Ahluwalia et 
al[110] 
Cross-sectional Examine the 
association of MetS 
definitions  with 
carotid  and 
femoral plaques 
Random sample of  
N= 11543 French 
adults aged (35-65 
years) 
Carotid  and 
femoral plaque 
WHO 
NCEP-ATP 
III 
Risk of subclinical 
atherosclerosis ( 
plaque) associated 
with MetS 
regardless of the 
definitions used 
First study to include 
inflammatory factors in 
assessing the relationship 
between MetS and 
subclinical  CVD 
Ma et al[111] Cross-sectional Compare the 
relationship 
between 
Subclinical 
atherosclerosis and 
MetS 
140 non-diabetic 
participants aged 
(38-50) years 
Carotid IMT IDF 
AHA/NHLBI 
NCEP-ATP 
III 
WHO 
No association 
between carotid 
IMT and MetS 
defined by NCEP-
ATP III or WHO. 
MetS definitions by 
IDF and 
AHA/NHLBI 
criteria are the best 
among four 
definition in 
detecting subclinical 
atherosclerosis in 
non-diabetic 
Chinese subjects 
Small sample size 
Tzou et 
al[112] 
Longitudinal Investigate the 
association of MetS 
with subclinical 
507 non-diabetic 
subjects from 
Bogalusa Heart 
 Common 
carotid IMT; 
Internal  and 
NCEP-ATP 
III, WHO 
MetS associated 
with increased 
atherosclerotic 
Multi-ethnic sample and  
findings can easily be 
generalized to the 
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Authors Study  Design Objective Study Population Subclinical 
CVD 
measures 
Metabolic 
syndrome 
(MetS) 
Results/Findings Strengths/Limitations 
atherosclerosis Study bulb  IMT burden and 
increased 
cardiovascular risk 
broader population 
Herder et 
al[113] 
Longitudinal Assesses MetS and 
progression of 
atherosclerosis 
1442 men and 1532 
women from 
Tromso study 
Carotid IMT; 
Total Plaque 
area 
NCEP- ATP 
III 
Participants with 
MetS had higher 
levels of IMT and 
Total plaque area at 
follow up. MetS 
predicted 
progression of IMT 
and TPA in those < 
50 years of age. 
High attrition  rate 
Selection bias due to 
higher mortality in those 
without MetS 
Bonora et 
al[105] 
Longitudinal Prospectively 
evaluating  carotid 
atherosclerosis  and 
coronary heart 
disease in subjects 
with the MetS 
888 subjects  with 
MetS aged 40-79 
years  
Common 
carotid artery; 
Carotid plaque 
WHO 
NCEP-ATP 
III 
Subjects with the 
MetS are at 
increased risk for 
both progressive 
carotid 
atherosclerosis and 
CHD 
Population-based study 
participants 
First study to evaluate 
atherosclerosis in 
participants with MetS 
prospectively 
Hassinen et 
al[114] 
Longitudinal Investigate 
association of MetS 
and progression of  
carotid IMT 
101 elderly women NCEP-ATP 
III 
MetS associated 
with progression of 
carotid IMT in 
women 
Small sample size 
Koskinen et 
al[92] 
Longitudinal Evaluate  
conventional risk 
factors and MetS 
progression of IMT 
in young  adults 
1809 young adults 
aged ( 32±5 years) 
Carotid IMT NCEP-ATP 
III 
EGIR 
IDF 
MetS via all 
definitions identified 
young adults with 
accelerated  IMT 
progression 
High attrition rate 
Homogenous population 
therefore cannot 
generalized the findings 
to other ethnicities 
CVD, Cardiovascular disease; CHD, Coronary Heart Disease; IDF, International diabetes Federation; WHO, World Health Organization; NCEP- ATP III, National 
Cholesterol Education Program Adult Treatment Panel III; US, United States;  EGIR, The European Group for the  Study of Insulin Resistance; AHA/NHLBI, 
American Heart Association/ National Heart, Lung and Blood Institute; 
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Table 1-3 Continued
2.0  ARTERIAL REMODELING IN HEALTHY MIDLIFE WOMEN 
2.1 Structure of Arterial Wall 
Figure 2-1 Structure of Arterial Wall 
Adapted from Vascular Concepts http://www.vascularconcepts.com 
The arterial wall is composed of three distinct layers (Figure 2-1).  The most interior of 
the layers is the tunica intima, also known as the intima, and is mainly composed of an elastic 
membrane lining and an endothelium that is covered by elastic tissues.  The middle layer, tunica 
medial, consists of smooth muscle cells and elastic tissue.  The outermost layer, tunica adventitia 
also known as the adventitia is comprised up of connective tissue [115-117] 
2.2 Pathophysiology of Arterial Remodeling 
Arterial remodeling (AR) refers to a number of structural and functional changes of the 
vascular wall that occur in response to disease, injury, and aging [118],  and can be divided into 
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atherosclerotic and arteriosclerotic processes.  Atherosclerosis is initiated by inflammation in the 
intima by the accumulation of lipids in plaques, whereas arteriosclerosis is characterized by more 
diffuse changes of the medial arterial vascular wall [119].  The processes central to AR (Figure 
2-2) are  migration and proliferation of vascular smooth muscles cells, degradation and fracture 
of elastin fibers, and calcification and deposition of extracellular matrix (ECM) material [118]. 
Endothelial cells, elastic tissue and smooth muscle cells are subject to constant stimuli 
and mechanical forces, and given this, adaptations take place over time.  The atherogenic factors 
such as lipid oxidation products response to injury and hemodynamic stimuli potentially induce 
arterial damage [120-122].  Given that basal levels of tensile stress are sustained based on 
Laplace’s law, which states that the larger the vessel radius, the larger the wall tension required 
to withstand a given internal fluid pressure, thickening of the vessel wall via proliferation and 
migration of smooth muscles cells occurs [121, 123].  Endothelial cells are important because 
they ensure normal vascular adaption to chronic changes in blood flow and blood pressure [124]. 
Endothelial dysfunction, a feature of arterial aging, is suspected to be caused by nitric oxide 
deficiency or the development of oxidative stress, both of  which help  in  inducing the 
remodeling  response [124]. 
Different patterns of remodeling are suggested in the literature (Figure 2-3).  Outward 
remodeling refers to an increase in flow, and it is dependent on   shear induced endothelial 
production of nitric oxide [120, 125] and the gelatinase matrix metalloproteinase (MMPs) MMP-
2 and MMP-9 [126].  Nitric oxide is at the core of this process largely because it is believed  to 
mediate vessel wall remodeling by regulating expression of MMPs [127].  Inward remodeling 
occurs in the low-flow state, where an increase in production of mitogenic and fibrogenic growth 
factors along with their potential factors mediate to increase smooth muscle cell proliferation 
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and collagen deposition to reorganize vessel structure [125, 128, 129].  AR coupled with changes 
in circumferential wall tension and circumferential wall stress is termed maladaptive AR [130-
132], whereas AR without changes in transmural pressure is considered compensatory adaptive 
enlargement of the arterial wall [133]. 
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Figure 2-2 Pathophysiological Mechanisms of Arterial Remodeling
Adapted from Varik et al[134] 
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Figure 2-3 Types of Vascular Remodeling
   Adapted from Mulvany et al [135] 
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3.0  METHODS OF ASSESSING ARTERIAL REMODELING 
There is tremendous interest in identifying asymptomatic individuals at high risk of CVD 
who might be candidates for more intense and evidence-based medical intervention that may 
help to reduce CVD risk. Measurements of carotid intima-media thickness (IMT), carotid plaque, 
adventitial diameter (AD), and lumen diameter (LD) are markers of arterial health.  These 
markers may be measured with B-mode ultrasound, which is a noninvasive, sensitive, and 
reproducible methods for identifying and quantifying subclinical atherosclerosis [136]. 
3.1 Carotid intima-media thickness 
Carotid IMT is a measurement of the thickening of the tunica intima and the tunica media 
of the arterial wall.  The measurement is usually made by  B-mode ultrasound, which is 
noninvasive, sensitive and reproducible [137]. Measures of carotid IMT are associated with CVD 
risk factors, as well as prevalent and incident CVD [136]. Given these features, carotid IMT is 
considered as a surrogate marker of atherosclerosis.  
In diverse study populations, carotid IMT has been found to be associated with 
atherosclerotic and CVD risk factors [138].  In a recent systematic review, carotid IMT (relative 
risk (RR), 1.26)) was found to be associated with future CVD events, as evidenced by a one 
standard deviation increase in carotid IMT being predictive for myocardial infarction and stroke 
[139].  
MetS has been shown to be significantly associated with higher  mean carotid IMT 
(Table 1-3)  and the presence of coronary heart disease (CHD) [104].  Both cross-sectional and 
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prospective studies have found an association between MetS and carotid IMT [85, 94, 110]. 
Among US middle-aged adults, MetS was associated with progression of carotid IMT after 
adjusting for traditional CVD risk factors [140]. The components of MetS that either attenuate or 
accentuate the association between MetS and carotid IMT appear to vary by gender.  HDL-c and 
glucose had varying impact in men and women, respectively.  It was also shown that the 
association between MetS and subclinical atherosclerosis measures, such as carotid IMT, varied 
by gender with females with MetS having greater mean carotid IMT than men with MetS [141, 
142]. However, among postmenopausal women, limited data regarding the association between 
MetS and subclinical atherosclerosis exist.  
 3.2 Carotid plaque 
Carotid plaque refers to atherosclerotic lesion characterized by focal thickening in intimal 
layer and typically composed of lipid core and connective tissues.   Carotid plaque tend to 
develop in arterial regions subjected to low wall shear stress and turbulent flow, such as carotid 
bulb [143]. It is also defined as a distinct area protruding into the vessel lumen that is at least 
50% thicker than the adjacent IMT [144].  Carotid plaque is associated with traditional CVD risk 
factors, coronary ischemia and angiographic coronary artery disease [145].   The presence of 
carotid plaque is associated with larger mean values of carotid IMT, and has been shown to 
predict future CVD events [146]. In some instances, carotid plaque was found to be a stronger 
predictor of incident CVD events than that of carotid IMT [74] therefore the presence of carotid 
plaque is a useful screening tool for predicting future CVD[147].  MetS is independently 
associated with calcified and non-calcified plaques [148] but has not been shown to be 
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consistently associated with plaque.  In a Japanese study, MetS was not found to be an 
independent risk factor for carotid plaque or carotid IMT [149].  In a prospective study over a 13 
year period, participants with MetS had a higher total plaque area (TPA) compared to those 
without MetS [113].  However, the presence of MetS only predicted progression of total plaque 
area among those below 50 years of age, suggesting that MetS may play a significant role in the 
processes involved in the early atherosclerotic formation. 
3.3 Adventitial diameter 
Adventitial diameter (AD) is a marker of vascular health and [144] is the measured 
distance from the adventitial-medial interface on the near wall to the medial-adventitial 
interfaces on the far wall.  The measure of AD is reliable and reproducible [37].  AD is 
associated with CVD risk factors and overt CVD.  Individuals with pre-existing atherosclerosis 
or atherosclerosis risk factors have larger mean AD than individuals without those characteristics 
[150].   
MetS is associated with greater AD [151, 152].  Several components of MetS are also 
positively associated with AD.  In a cross-sectional study of middle-aged women, those with 
MetS were found to have significantly greater values of AD compared to those without MetS 
[152]. In a population-based cohort of healthy participants, steeper increases in AD were 
observed over time among participants with persistent MetS compared to those who were never 
classified as having MetS while adjusting for other CVD risk factors [131].  In a cross sectional 
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study of older healthy participants without diabetes, MetS was found to be associated with 
greater AD after adjusting for low-grade inflammation and hemodynamic factors [130]. 
3.4 Lumen diameter 
Lumen diameter (LD) can be measured noninvasively using carotid ultrasound imaging 
technique.  It is a reliable and reproducible measure, if measured non-invasively [75].  Greater 
LD is independently associated with higher systolic blood pressure, BMI, mean arterial pressure, 
total cholesterol and carotid IMT and with pre-existing coronary disease [153]. 
Mets is independently associated with greater LD after adjusting for traditional CVD risk 
factors and prior CVD. The association was attenuated slightly but remained statistically 
significant after additional adjustment for important metabolic, inflammatory and hemodynamic 
variables [130]. In the Women’s Angiographic Vitamin and Estrogen trial (WAVE), the annual 
LD measurement decreased among participants with MetS compared to those free of MetS, but 
the change was not statistically significant.  In a multivariable analysis, MetS was not 
independently associated with a reduction in mean LD over time [154]. 
3.5 Circumferential wall tension (CWT) 
Circumferential wall tension measures the transmural pressure in the blood vessel.  CWT 
is estimated according to Laplace’s law [130, 155, 156]. It is determined using LD and mean 
arterial pressure (MAP) and is calculated as: CWT = MAP*(Lumen diameter/2). Higher mean 
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CWT  has been shown  to be associated with  strokes as evidenced by higher carotid CWT  
measured on the  affected side of stroke patients [132]. 
In a cross-sectional study among non-diabetic participants, MetS was significantly 
associated with higher mean CWT [130]. In population-based study, higher mean? levels of 
CWT were associated with  both higher levels of waist circumference and blood pressure [131]. 
3.6 Circumferential wall stress (CWS) 
Circumferential wall stress measures blood vessels respond to changes in transmural 
pressure. By the Laplace’s law, CWS is computed as CWS = CWT/ IMT, where IMT = carotid 
IMT, and CWT = Circumferential wall tension [130, 132]. 
CWS is associated with MetS.  Beijers et al have reported that non-diabetic individuals 
with MetS had greater CWS compared to those without MetS.  Even among those with MetS, 
higher levels of CWS were significantly associated with a larger waist circumference and higher 
mean blood pressure [131]. 
3.7 Cross-sectional Area (CSA) 
Arterial wall cross-sectional (CSA) is a measure of vascular volume or mass, and 
represent arterial wall thickening associated with atherosclerosis[157]. CSA is calculated as 
π*IMT*(IMT+LD), where LD is Lumen diameter [131, 157]. 
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In a population-based cohort study, increases in mean CSA were significantly associated 
with changes in systolic blood pressure. Individuals with persistent MetS were found to have 
significant and steeper increases in mean CSA even after adjusting for blood pressure over 6 
years period [131]. 
4.0  EPIDEMIOLOGY OF ARTERIAL REMODELING IN MIDLIFE 
WOMEN 
Arterial remodeling (AR) is fundamental to many arterial diseases and in particular AR is 
one of the major determinants of clinical manifestations of coronary disease such as myocardial 
infarction and stroke [158]. The relationships between traditional CVD risk factors and AR are 
not fully understood.  Thus far, the evidence shows that CVD risk factors such as hypertension 
and hypercholesterolemia are associated with both positive and negative remodeling of the artery 
[159].  Carotid plaque, hypertension and coronary flow reserve, after adjustment for other 
traditional CVD risk factors, have been shown to be independent predictors of AR [159, 160].  
Among non-obese postmenopausal women, waist-to-hip ratio, a marker for central adiposity, 
was associated with AR after adjusting for body mass index, age and lipid profile [161]. 
Variations in AR have been reported in the literature.  Among middle-aged women 
transitioning through the menopause in the SWAN study, Woodard et al found different levels of 
carotid plaque among White women compared to African American women [162]. Whether this 
racial difference explains incident CVD morbidity or mortality is not known.  The presence and 
burden of carotid plaque also differed by sex, and at any given age men tend to have more plaque 
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than women. Sex hormones are thought to be the driving force behind the difference in term of 
carotid plaque [139].  
AR has been shown to be associated with MetS [130, 152, 163].   In a population-based 
cohort, MetS was significantly associated with maladaptive remodeling of the carotid artery, 
resulting in higher changes in LD, AD and carotid IMT, independent of hemodynamic variables. 
An outward remodeling pattern was noted along with greater mean circumferential wall tension 
and  circumferential wall stress [130].   In a cross-sectional study, Iannuzzi et al reported a 
positive association between MetS and changes in carotid structure among middle-aged women 
[152].  In a population based study of elderly men and women, MetS was significantly associated 
with alterations in the structure of the carotid structure of the carotid arteries after adjustment for 
conventional CVD risk factors [163].  
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5.0  SPECIFIC AIMS 
The metabolic syndrome (MetS) is a collection of risk factors associated with higher risk 
of heart disease, stroke and diabetes [15]. Various definitions and criteria exist for the 
classification of MetS and nearly all consist of the following factors:  elevated blood pressure, 
central obesity,  dyslipidemia, and impaired glucose [10]. The  components of MetS are 
interrelated and share underlying factors, mechanisms and pathways leading to their 
development [17].  This dissertation uses data from the Study of Women’s Health Across the 
Nation (SWAN) to examine MetS and its association with subclinical atherosclerosis, common 
carotid artery remodeling and related risk factors.   Furthermore, the effects of MetS status 
measured over time on carotid remodeling in women of midlife will be examined. 
The major aims of this dissertation are as follow: 
1. To compare the association between IDF, NCEP-ATP III, and WHO definitions of MetS
and subclinical atherosclerosis among middle-aged women, as well as examine individual
components of MetS and its association with subclinical atherosclerosis.
2. To examine the relationship between MetS and common carotid artery remodeling and
the pattern of remodeling associated with it in non-diabetic midlife women.
3. To assess the effects of MetS status and its individual components changes on common
carotid artery parameters over time in midlife women.
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6.1 ABSTRACT 
Objective: The aim of this study was to compare the association between subclinical 
atherosclerosis and metabolic syndrome defined using three well-recognized definitions among 
older middle-aged women to determine which of the definitions is associated with worse 
subclinical atherosclerosis profile. 
Methods: Participants from 6 sites of the Study of Women’s Health Across the Nation (SWAN) 
free of clinical cardiovascular disease and who had measures of carotid intima-media thickness 
(IMT) and carotid plaque (CP) at the 12th annual visit were analyzed.  Women were identified as 
having MetS if they met the criteria defined by the International Diabetes Federation (IDF), 
National Cholesterol Education Program Adults Treatment Panel III (NCEP-ATP III) and World 
Health Organization (WHO) criteria.  Multivariable linear and logistic regression models were 
used to investigate the association between the presence of MetS with IMT and CP while 
adjusting for age, study site, race/ethnicity, BMI, LDL-C, smoking status, menopausal status, 
hormone use and education level.  
Results: The presence of MetS was significantly and positively associated with IMT for all three 
definitions (all p<.0001). After adjusting for covariates, MetS remained positively and 
significantly associated with IMT (IDF β = 0.0303 (p < .0001), NCEP-ATP III β =0.0274 
(p<.0001), WHO β =0.0570 (p<.0001)).   The WHO construct was more strongly associated 
with IMT compared to both the IDF and the NCEP- ATP III definitions.  MetS was also 
significantly associated with the presence of CP (IDF Odds Ratio [OR] =1.61 [95% Confidence 
Interval [CI] 1.30-2.01], NCEP-ATP III OR=1.68 [95% CI 1.35-2.10], WHO OR =1.68 [95% CI 
1.27-2.24). After controlling for covariates, MetS remained significantly associated with a 70% 
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to 98% higher risk in the presence of CP compared to those without MetS with the WHO 
definition conferring the highest risk. 
Conclusions: The presence of MetS using three definitions was significantly associated with 
greater burden of subclinical atherosclerosis measures in older middle-aged women. The WHO 
definition was the best in identifying older middle-aged women with a worse subclinical 
atherosclerosis profile, followed by IDF, and then NCEP-ATP III. 
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6.2 INTRODUCTION 
Metabolic syndrome (MetS), a clustering of cardiovascular disease (CVD) related risk 
factors consisting of abdominal obesity, dyslipidemia, hypertension and hyperglycemia [164, 
165], is associated with both incident type 2 diabetes mellitus and CVD events [82] and is one of 
the significant public health challenges faced by both developed and developing countries [165].  
While several definitions are used to classify MetS status, most incorporate similar criteria.  The 
key diagnostic criteria were first put forth by the World Health Organization (WHO) in 1998, 
followed by the European Group for the study of Insulin Resistance (EGIR) in 1999, the 
National Cholesterol Education Program’s Adult Treatment Panel III (NCEP-ATP III) in 2001, 
and the International Diabetes Federation (IDF) in 2005.  The main differences among the 
various definitions are (1) the inclusion/exclusion of features that define criteria such as use of 
pharmacological treatments, (2) specific cut points that determine criteria like fasting glucose ≥ 
110 mg/dL or ≥ 100 mg/dL and (3) the compulsory inclusion of central obesity and diabetes.   
Despite the  various options in definitions, the NCEP-ATP III definition is most commonly used 
in epidemiological and clinical practice worldwide for its ease of assessment [166]. 
Beyond overt CVD events, MetS, as defined by NCEP-ATP III [167], IDF and 
AHA/NHLBI[109], and WHO[164], has been shown to be significantly associated with markers 
of subclinical atherosclerosis including higher mean carotid intima-media thickness (IMT), 
arterial stiffness and the  presence of carotid plaque. It is believed that  measures of subclinical 
atherosclerosis are surrogate markers of pre-clinical CVD, and  over time such measures are 
associated with CVD events [139].  While MetS is associated with the presence of subclinical 
atherosclerosis in many epidemiological studies [110, 168], other reports have found no 
44 
association between MetS and subclinical atherosclerosis after adjustment for individual MetS 
components [164, 169].   
Various MetS definitions are linked to subclinical atherosclerosis in middle-aged adults.  
In a prospective study, Hassinen et al. reported that incident MetS was associated with 
accelerated progression of carotid IMT in elderly women [170].   In a population - based study 
conducted in Korea among participants 50 years and older, the presence of MetS was associated 
with subclinical atherosclerosis, and the association was more pronounced among women 
compared to men [171]. The published findings show an association between MetS and 
subclinical atherosclerosis, yet questions remain regarding the clinical utility of the various 
constructs of MetS.  Moreover, findings from The Study of Women’s Health Across the Nation 
(SWAN) indicate that the prevalence of MetS increases through the menopausal transition and is 
independent of age, potentially implicating changes in hormone [172].  Data is lacking in 
women, and it is, therefore, important to assess the performance of various definitions of MetS in 
identifying the risk for CVD based on subclinical atherosclerosis measures.   
We therefore sought to compare the association between the IDF, NCEP-ATP II and 
WHO definitions of MetS and subclinical atherosclerosis among older middle-aged women.   We 
also examined individual components of MetS and its association with subclinical 
atherosclerosis to determine which of the definitions is associated with worse subclinical 
atherosclerosis profile. 
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6.3 METHODS 
 
6.3.1 Study Population 
 
The Study of Women’s Health Across the Nation (SWAN) is a multiethnic, community-
based, longitudinal study of the natural history of the menopausal transition in a cohort of 3302 
women enrolled at 7 field sites throughout the United States (Boston, Massachusetts; Chicago, 
Illinois; Detroit, Michigan; Los Angeles, California; Oakland, California; Newark, New Jersey; 
and Pittsburgh, Pennsylvania).  The design of the study has been described previously [173].  
The cohort, at the baseline, consisted of non-pregnant White, Black, Chinese, Japanese and 
Hispanic women, aged 42 to 52 years, with an intact uterus and at least one ovary, having had at 
least one menstrual period in the preceding 3 months, and not using hormone therapy in the 
preceding 3 months.   
 
The sample size of the current analysis consisted of participants who had a carotid 
ultrasound examination during the 12th follow-up clinic visit.  The University of California at 
Los Angeles site did not participate in the carotid ultrasound protocol and is therefore not 
included in this analysis. Of 3302 women enrolled at the baseline, 1552 underwent a carotid 
artery ultrasound examination.  Among participants who participated in the carotid ultrasound 
protocol, 45 women were removed from the analysis due to missing IMT data.  An additional 66 
participants were excluded due to missing data pertaining to MetS criteria, leaving a final sample 
size of 1441 participants (Figure 6-1).   The institutional review board at each participating site 
and at the Data Coordinating Center located at the University of Pittsburgh approved the study 
protocol. 
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6.3.2 Assessment of cardiovascular and metabolic risk factors 
 
All study participants underwent annual or biannual study visits consisting of 
interviewer-administered questionnaires to ascertain medication use, medical history, lifestyle 
characteristics and menopausal status, physical measures, and a fasting blood draw for 
assessment of cardiovascular risk factors and reproductive hormone levels.  Race or ethnicity 
was self-reported.    
 
Blood pressure was measured in the right arm, while participants were seated with feet flat on 
floor following at least 5 minutes of sitting quietly before measurements were taken.  A standard 
mercury sphygmomanometer was used to measure systolic and diastolic pressures at first and 
fifth korotkoff sounds.   The average of two sequential readings was used in the analyses.  Height 
was measured without shoes using a stadiometer.  Weight was measured with light indoor 
clothing using calibrated scales. Waist circumference was measured with participants in light 
undergarments.   
 
Lipids, glucose, and insulin measured using a Siemens ADVIA 2400 automated 
chemistry analyzer utilizing Siemens ADVIA chemistry system reagents (Siemens Healthcare 
Diagnostics, Deerfield IL) at the University of Michigan Pathology Laboratory, which is Clinical 
Laboratory Improvement Amendments (CLIA) certified and accredited by the College of 
American Pathologists. Triglycerides, high-density lipoprotein cholesterol (HDL-C) and directly 
measured low density lipoprotein cholesterol (LDL-C) [174] were analyzed using a coupled 
enzymatic methods that utilized lipase, glycerol kinase, glycerol-3-phosphate oxidase (G3PO), 
and peroxidase (for triglycerides) and cholesterol esterase, cholesterol oxidase, and peroxidase 
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(for HDL-C and direct LDL-C). Serum insulin was measured by a two-site sandwich 
immunoassay using direct chemiluminescent technology that used constant amounts of two 
antibodies. Glucose was measured using a two-step enzymatic reaction that utilized hexokinase 
and glucose-6-phosphate dehydrogenase (G6PDH) enzymes. Diabetes was defined as either 
fasting glucose ≥ 126 mg/dL, a diagnosis of diabetes by physicians or anti-diabetic medication 
treatment.  
 
 6.3.3 Metabolic syndrome definitions 
 
NCEP-ATP III metabolic syndrome definition 
  
The NCEP-ATP III definition of the MetS consists of the following five factors: central 
obesity (waist circumference > 102 cm for men, > 88 cm for women), elevated triglycerides (≥ 
150 mg/dL), elevated blood pressure (systolic blood pressure ≥ 130 mmHg/diastolic blood 
pressure ≥85) or medication for hypertension, fasting plasma glucose (≥ 100 mg/dL) and reduced 
HDL cholesterol (< 40 mg/dL for men, < 50 mg/dL for women) [175]. An individual with three 
or more of the above factors was classified as having MetS. 
 
 
IDF metabolic syndrome definition 
 
The IDF definition of MetS consists of the same factors as NCEP-ATP III definitions. 
Within the IDF definition, central obesity is required to be a component of the criteria, plus two 
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or more of the other factors. The components of IDF are as follows: waist circumference ≥ 94 cm 
for European men, and ≥80 cm for European women and other ethnicity-specific values for other 
racial/ethnic groups; triglycerides ≥150 mg/dL; systolic blood pressure ≥130 mmHg or diastolic 
blood pressure ≥85 mmHg or treatment of previously diagnosed hypertension; HDL <40 mg/dL 
in men and < 50 mg/dL in women; fasting glucose ≥ 100 mg/dL [176].  
 
 
WHO metabolic syndrome definition 
  
The WHO definition consists of the same factors that comprise the other definitions with 
the exception of the requirement of insulin resistance (abnormal glucose regulation or type 2 
diabetes, or fasting plasma glucose ≥110 mg/dL).  Two or more of the following components are 
also required: triglycerides ≥150 mg/dL; systolic blood pressure ≥140 mmHg or diastolic blood 
pressure ≥90 mmHg or current use of antihypertensive; HDL <35 mg/dL in men and < 39 mg/dL 
in women; body mass index (BMI) > 30  or  waist-to-hip ratio (WHR)  >0.9 in men or  > 0.85 in 
women; urinary albumin creatinine ratio ≥ 30 mg/g after overnight fast [18].  
 
6.3.4 Carotid intima-media thickness and plaque 
 
Centrally trained and certified sonographers obtained carotid ultrasound images using a 
Terason t3000 Ultrasound System (Teratech[177] Corp, Burlington, MA) equipped with a 
variable frequency 5-12 Mhz linear array transducer.  Two digitized images were obtained of 
each of the left and right distal common carotid artery (CCA).  From these 4 images and using 
the  Artery Measurement System (AMS) semi-automated edge detection software [178], near 
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and far wall CCA intima-media thickness (IMT) measures were obtained by electronically 
tracing the lumen-intima interface and the media-adventitia interface across a 1-cm segment 
proximal to the carotid bulb. The average and maximal values for these measures were recorded, 
with the mean of the average and maximal readings of all 4 images used in analyses.  All carotid 
scan images were read centrally at the SWAN Ultrasound Reading Center (University of 
Pittsburgh Ultrasound Research Lab) by two trained readers.  Clinic site sonographers evaluated 
the presence and extent of atherosclerotic plaque in each of 5 segments of the left and right 
carotid artery (distal and proximal common carotid artery, carotid bulb, and proximal internal 
and external carotid arteries) [179].  Plaque was defined as a distinct area protruding into the 
vessel lumen that was at least 50% thicker than the adjacent IMT and summarized as the 
presence or absence of any plaque. Reproducibility of IMT measures was good to excellent with 
an intraclass correlation coefficient between sonographers of   ≥ 0.77, and between readers of   > 
0.90. The assessment of atherosclerotic plaque was found to be a valid and reproducible measure 
of carotid atherosclerosis in a number of populations based studies, with intraclass correlations 
ranging from 0.86 to 0.93 [180].  
 
 
6.3.5 Statistical analyses 
  
The MetS status for each participant was classified based on each of the 3 definitions 
described above.  Descriptive statistics were summarized as means or medians for continuous 
variables and percentages for categorical variables. Normality for all continuous variables was 
assessed and comparisons between those with and without MetS were made by the Wilcoxon-
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rank sum test or Student’s t-test.  The Chi-square test was used to compare nominal variables 
between MetS and non-MetS groups.   
 
Multivariable linear and logistic regression analyses were used to evaluate the association 
between each of the MetS definitions and its individual components and measures of subclinical 
atherosclerosis (carotid IMT and carotid plaque presence (yes/no), respectively).  The unadjusted 
models assessed the univariate relationship between MetS status and both carotid IMT and 
plaque.  All models were then adjusted for age, race/ethnicity, study site, menopausal status, 
education, smoking, body mass index, LDL-c, and use of hormone therapy medications. This set 
of variables was selected due to the design of the SWAN study and based on known risk factors 
with subclinical atherosclerosis in the literature.   To assess the relationship between individual 
components of MetS and carotid IMT and plaque, separate models were developed that included 
the individual components of each MetS definitions while adjusting for standard set of 
covariates.   
 
To explore which of the MetS definition correlated better with measures of subclinical 
atherosclerosis, model diagnostics were evaluated.  Unadjusted and adjusted R-squared of each 
model were used to examine for outcomes of IMT and receiver operating curves (ROC) were 
used to examine the performance of each of the MetS models for carotid plaque.    All statistical 
analyses were performed with the use of SAS software, version 9.3, and a two-sided P-value of 
0.05 or less was considered to indicate statistical significance. 
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6.4 RESULTS 
 
The 1441 participants in this study were comprised of 30.5% (n = 439) Blacks, 51.1% (n 
= 736) Whites, 12.8% (n = 185) Chinese and 5.6% (n = 81) Hispanic women.  The average age 
of participants was 59.6 ±2.7 years (Table 6-1).   In all, 36.4% of the study participants fulfilled 
at least one of the three MetS definitions considered in the study.  Classifying participants by 
MetS definition, 34.6% met IDF criteria, 32.2 % met NCEP-ATP III criteria and 15.9% met the 
WHO definition (figure 6-2).   Among participants with MetS, 204 (14.2%) fulfilled all three 
definitions for Mets.   
 
In each of the MetS definitions, the prevalence of MetS was higher among Hispanic 
women (Table 6-2).  As expected, participants with MetS had higher mean body mass index, 
waist circumference, waist-to hip ratio, systolic blood pressure, diastolic blood pressure, fasting 
plasma glucose, and triglycerides compared to those without MetS.  With respect to total 
cholesterol, participants without MetS had higher mean levels compared to those with MetS in 
all definitions likely due to the higher use of cholesterol modifying medications among those 
with MetS.  Across all definitions, participants with MetS had a significantly greater average 
carotid IMT and a higher prevalence of carotid plaque compared to those without MetS. 
 
MetS was significantly and positively associated with carotid IMT in all three definitions 
(all p<.0001) (table 6-3).  Even with adjustment, all MetS definitions remained significantly and 
positively associated with carotid IMT (IDF β = 0.0303 (p < .0001), NCEP-ATP III β =0.0274 
(p<.0001), WHO β =0.0570 (p<.0001)) (Table 6-3).   The WHO construct was more strongly 
associated with carotid IMT compared to the IDF and the NCEP- ATP III definitions as assessed 
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by the higher r-squared and adjusted r-squared (Table6-4).  The difference, however, between the 
IDF and NCEP-ATP III definition was minimal. With the removal of participants with diabetes, 
the findings were nearly the same between IDF and NCEP-ATP III constructs in correlating with 
carotid IMT. 
 
All MetS definitions were significantly associated with the presence of carotid plaque 
(IDF Odds Ratio [OR] =1.61 [95% Confidence Interval [CI] 1.30-2.01], NCEP-ATP III OR=1.68 
[95% CI 1.35-2.10], WHO OR =1.69 [95% CI 1.27-2.24).   Even after adjusting for age, 
race/ethnicity, clinic site, menopausal status, education, smoking status, LDL, body mass index, 
and hormone therapy use, all MetS definitions remained significantly associated with a 70% to 
98% higher risk in the presence of carotid plaque compared to those without MetS.  The area 
under the curve analysis for each of the MetS definitions was significant, but there was no 
difference with respect to their performance in discriminating the presence of carotid plaque in 
both unadjusted and adjusted models (Table 6-5) and (FIGURE 6-3).  When removing 
participants with diabetes, no significant differences were observed with respect to the 
performance of the MetS constructs in relation to the presence of carotid plaque. 
 
To examine the relationship between each of the individual components of MetS 
definitions and subclinical atherosclerosis, a series of unadjusted and adjusted multivariable 
regression models were performed.  Using the IDF definition, higher blood pressure, waist 
circumference and fasting glucose were independently associated with carotid IMT, β = 0.0273 p 
<0.0001, β = 0.0293, p = 0.0009 and β= 0.0264, p =0.0002, respectively (table 5).   Similarly, 
blood pressure, waist circumference and fasting glucose were the individual components of the 
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NCEP-ATP III definition that were significantly associated with carotid IMT, β = 0.0276, p 
<0.0001, β = 0.0182, p = 0.0330 and β= 0.0272, p= 0.0001, respectively.  The components of the 
WHO definition significantly associated with IMT included blood pressure (β = 0.0293, p 
<.0001) and fasting glucose (β = 0.0211, p =.0098) (Table 6-6).  For carotid plaque, higher 
fasting glucose and blood pressure were the individual components significantly associated with 
presence of carotid plaque in all three definitions (table 6-7).   Additionally, body mass index 
was also independently associated with presence of carotid plaque in the WHO definition.  
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6.5 DISCUSSION 
 
The present study investigated the association between three commonly used definitions 
of MetS, namely IDF, NCEP-ATP III and WHO, and measures of subclinical atherosclerosis 
among older middle-aged women.  We found that MetS, via all definitions, was significantly 
associated with measures of subclinical atherosclerosis.  The WHO definition was more strongly 
associated with carotid IMT and carotid plaque presence compared to either the NCEP-ATP III 
or the IDF definitions.   The MetS components most strongly and consistently associated with 
carotid IMT and plaque were blood pressure and fasting glucose across all definitions considered 
in the current study. 
 
This current study found the MetS construct to be significantly associated with a greater 
burden of subclinical atherosclerosis in middle-aged women.  Our results suggest that the WHO 
definition was the best in identifying middle-aged women with a worse subclinical 
atherosclerosis profile, followed by IDF, and then NCEP-ATP III.  In our sensitivity analysis, 
where participants with diabetes were excluded, similar findings were observed.  We also found 
that the overall MetS construct was useful for assessing the burden of subclinical atherosclerosis, 
although not independent of individual components of the MetS definitions.  Some studies have 
reported no association between MetS and subclinical atherosclerosis [180, 181], whereas, others 
have raised questions about the clinical utility of the MetS construct regardless of the definition  
[177].  A number of other studies have shown that the association between MetS and subclinical 
atherosclerosis is more pronounced in women than men [101, 109, 182-184].  This finding has 
led some to suggest that the protective effect of  the female sex against atherosclerosis is lost in 
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the presence of MetS [184].  However, Skilton et al reported no sex difference with respect to the 
effect of MetS on subclinical atherosclerosis[109].   
 
We observed differences in strength of association with respective to MetS definitions 
and burden of subclinical atherosclerosis. Of the MetS definitions considered in this analysis, the 
WHO definition identified the fewest number of participants with MetS largely due to its 
requirement of either existing diabetes or the higher levels of fasting glucose.  However, 
participants classified as having MetS according to the WHO definition, had a higher mean 
carotid IMT compared to those with MetS by the other definitions.   Still, all three of the MetS 
definitions considered in the current study were significantly associated with carotid plaque 
presence.  Again, the strongest of the associations was observed with the WHO definition, 
followed by NCEP-ATP III, and then IDF.  Similar to our findings, MetS, as defined by WHO 
and NCEP-ATP III definitions, was strongly associated with the presence of  subclinical 
atherosclerosis in middle-aged adults in a study conducted in France[110].  In the Northern 
Manhattan study comprised of White, Black, and Hispanics men and women, MetS, as defined 
by NCEP-ATP III, was significantly associated with subclinical atherosclerosis [185].  The 
Atherosclerosis Risk in Communities (ARIC) study, a  cohort of over 14,000 middle-aged adults, 
also reported an association between MetS and higher mean carotid IMT [104].  The IDF 
definition was found to be a better predictor of carotid atherosclerosis in middle-aged women by 
Skilton and colleagues compared to the NCEP-ATP III definition.  The hypothesized reason for 
this finding was  the inclusion of abdominal obesity in IDF definition[109]; however, we did not 
observe that in our study.  
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We also examined the relationship of individual components of MetS definitions and 
subclinical atherosclerosis.  Across each MetS definition included in this study, higher blood 
pressure and fasting plasma glucose were positively and significantly associated with carotid 
IMT, and the presence of plaque.  Elevated waist circumference was associated with carotid IMT 
but not with presence of carotid plaque in both the IDF and NCEP-ATP III definitions.  These 
findings are consistent with what has been reported in the literature.   Among middle-aged 
adults, Iglseder et al reported that fasting glucose was the most strongly associated of the 
individual MetS components with carotid IMT[182].  In the Bogalusa Heart Study, higher blood 
pressure was a significant predictor of  carotid IMT [167].  In The Rancho Bernardo study, 
hypertension was the only component of the MetS associated with coronary artery calcium 
progression, while hyperglycemia was a significant risk factor among the subset of  participants 
under 65 years of age [102].  In the Muscatine study, carotid IMT was positively and 
significantly associated with systolic blood pressure only in women [103].  Sipila et al reported 
significant associations between both blood pressure and waist circumference and carotid 
IMT[94].  There are, however, differences between the current study and previous studies.  
Despite differences in the MetS definitions and the ages of the cohorts in the Bogalusa Heart 
study and the Rancho Bernardo Study as compared to our study, the consistent findings lend 
credence to the adverse role played by blood pressure and glucose in development of 
atherosclerosis. 
The current study has a number of strengths, but also several limitations.  The sample 
consisted of community - dwelling women in whom subclinical atherosclerosis burden was 
assessed by centrally trained vascular sonographers with no knowledge of participants’ CVD risk 
factors.  The study sample was multi-racial and multi-ethnic and comprised of White, Black, 
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Chinese and Hispanic women.  To our knowledge, this is the first study to assess three 
commonly used MetS definitions and their individual components in relation to subclinical 
atherosclerosis in a racially/ethnically diverse group of middle-aged women.  However, given 
that this is a cross-sectional study and we can only speculate about cause and effect, and 
therefore caution must be taken in the interpretation of these findings. 
 
In conclusion, the MetS is associated with a greater burden of subclinical atherosclerosis 
in older middle-aged women. Of the individual MetS components, blood pressure and fasting 
plasma glucose were positively and independently associated with carotid IMT and presence of 
carotid plaque in this study whereas dyslipidemia was related to neither measure of subclinical 
CVD.  Finally, there were differences in the strength of associations between MetS definitions 
and subclinical atherosclerosis with the WHO definition being the most strongly associated, 
largely due to its requirement for the inclusion of diabetes, followed by IDF definition, and then 
NCEP-ATP III.  Our findings suggest that, irrespective of the MetS definition used, the presence 
of MetS is associated with subclinical atherosclerosis.  The identification of middle-aged women 
with MetS and treating their risk factors, especially blood pressure and blood glucose may aid in 
efforts to reduce the development of subclinical atherosclerosis. 
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6.6 TABLES AND FIGURES 
 
 
Table 6-1 Participant characteristics 
Variables N = 1441* Value 
Age (years)  59.6±2.73 
Race/Ethnicity (n, %)   
Blacks  439 (30.5) 
White  736 (51.1) 
Chinese  185 (12.8) 
Hispanic  81 (5.6) 
Metabolic syndrome traits   
BMI(kg/m2)  30.0±7.2 
Waist circumference (cm)  93.0±15.9 
SBP(mmHg)  122.1±16.9 
DBP(mmHg)  74.2±10.0 
Glucose(mg/dL)  93(86-101) 
Triglycerides(mg/dL)  102(75-141) 
HDL-c(mg/dL)  61.8±16.5 
T2DM   
Yes  187(13.0) 
No  1254(87.0) 
Other CVD risk factors   
Waist-Hip Ratio  0.84± 0.07 
Total cholesterol(mg/dL)  204.6±38.2 
LDL-c(mg/dL)  119.7±32.3 
BP medication use (n, %)   
Yes  593(41.2) 
No  848(58.8) 
Cholesterol medication   
Yes  449(31.2) 
No  992(68.8) 
Smoking   
Yes  130(9.1) 
No  1298(90.9) 
Subclinical Atherosclerosis   
Carotid IMT (mm)  0.79±0.12 
Carotid plaque (n, %)   
Yes  629(43.7) 
No  811(56.3) 
 
BMI, Body mass index; SBP, Systolic blood  pressure; DBP, Diastolic blood pressure; HDL-C, 
high-density lipoprotein-cholesterol; LDL-C, Low density lipoprotein cholesterol; T2DM, Type II 
diabetes mellitus; BP, Blood pressure medication; Carotid IMT, Carotid Intima-media thickness  
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Table 6-2 Participants characteristics by metabolic syndrome definitions 
   IDF NCEP-ATP III  WHO 
    Yes (N=499)      No (N= 942) Yes (N=464)  No (N=977)      Yes (N=229)     No (N=1212) 
Age (years) 59.7±2.9 59.5±2.6 59.7±2.8 59.5±2.7 59.9±2.9 59.6±2.7 
Race/Ethnicity (n, %) 
Black 197(38.4%) 246(26.3%) 172(37.1%) 267(27.3%) 84(38.0%) 359(29.3%) 
White 233(45.4%) 505(54.1%) 216(46.5%) 520(53.2%) 93(41.2%) 647(52.8%) 
Chinese 44(8.6%) 141(15.1%) 35(7.5%) 150(15.4%) 22(10.0%) 163(13.3%) 
Hispanic 39(7.6%) 42(4.9%) 41(8.8%) 40(4.1%) 24(10.9%) 57(4.7%) 
Traits of MetS 
BMI(kg/m2) 33.8±6.7 28.1±6.6a 34.4±6.6 28.0±6.5a 35.5±7.1 29.0±6.8a 
WC(cm) 103.2±14.3 87.6±13.9a 104.9±13.9 87.2±13.5a 107.1±13.5 90.4±14.9a 
SBP(mmHg) 128.6±17.2 118.6±15.6a 128.7±17.2 118.9±15.7a 130.1±18.7 120.5±16.0a 
DBP(mmHg) 76.2±10.1 73.2±9.7a 76.3±10.2 73.3±9.7a 75.5±11.0 74.0±9.8a 
Glucose(mg/dL) 104(95-118) 89(84-95)a 105(96-121) 89(84-95)a 118(110-145) 91(85-97)a 
Triglycerides(mg/dL) 143(101-193) 89(68-116)a 147(107-194) 90(68-116)a 149(104-200) 96(72-129)a 
HDL-C(mg/dL) 50.9±12.0 67.6±15.6a 50.0±11.2 67.4±15.6a 50.8±12.3 63.9±16.3a 
a P<.0001; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; HDL-C, High density lipoprotein; WC, Waist Circumference; T2DM, Type II Diabetes Mellitus; IDF, 
International Diabetes Federation; NCEP-ATP, National Cholesterol of Education Program’s Adult Treatment Panel III; WHO, World Health Organization 
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Table 6-2 Continued
          IDF NCEP-ATP III  WHO 
 Yes (N=499)      No ( N= 942) Yes ( N=465)  No ( N=976)      Yes ( N=229)     No ( N=1212) 
Other risk factors 
T2DM (n, %) 148(29.7%) 39(4.1%)a 148(31.8%) 39(4.0%)a 155(67.7%) 32(2.6%)a 
Waist-Hip Ratio 0.88±0.07 0.82±0.06a 0.88±0.07 0.82±0.06a 0.89±0.07 0.83±0.07a 
Total cholesterol (mg/dL) 194.0±40.3 210.3±35.9a 193.7±40.5 209.9±36.0a 187.3±38.1 208.6±37.2a 
LDL-C (mg/dL) 113.4±33.3 122.9±31.2a 113.1±33.4 122.7±31.2a 105.7±34.4 122.3±31.2a 
BP medication 363(70.7%) 235(25.2%)a 345(71.4%) 253(26.2%)a 192(86.9%) 406(33.1%)a 
Cholesterol medication 253(50.7%) 196(20.8%)a 240(51.6%) 209(21.4%)a 151(65.9%) 298(24.6%)a 
Smoking 66(13.4%) 64(6.8%)a 62(13.6%) 68(7.0%)a 32(14.1%) 98(8.2%)a 
Subclinical 
Atherosclerosis 
Carotid IMT(mm) 0.83±0.13 0.77±0.11a 0.83±0.13 0.78±0.11a 0.85±0.14 0.78±0.11a 
Carotid plaque (n, %) 256(51.4%) 373(39.6%)a 242(52.3%) 387(39.6%)a 125(54.6%) 504(41.6%)a 
a P <.0001; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; BMI, Body Mass Index; WC, Waist Circumference; T2DM, Type II Diabetes Mellitus; IDF, International 
Diabetes Federation; NCEP-ATP, National Cholesterol of Education Program’s Adult Treatment Panel III; WHO, World Health Organization
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Table 6-3 Association between metabolic syndrome and carotid IMT in middle-aged women 
 IDF               NCEP-ATP III    WHO 
β(SE) R2 β(SE) R2 β(SE) R2
All women 
Unadjusted 0.0545(0.006)* 0.0472 0.0552(0.006)* 0.0467 0.0712(0.008)* 0.0480 
Adjusted 0.0303(0.007)* 0.1466 0.0274(0.007)* 0.1438 0.0570(0.009)* 0.1501 
No DM 
Unadjusted 0.0426(0.007)* 0.0279 0.0429(0.007)* 0.0266 -- -- 
Adjusted 0.0187(0.007)* 0.1228 0.0168(0.008)* 0.1216 -- -- 
* p <.0001; Carotid IMT, Carotid Intima-Media Thickness; IDF, International Diabetes Federation; NCEP-ATP, National Cholesterol of Education Program’s Adult Treatment
Panel III; WHO, World Health Organization; DM, Diabetes Mellitus;  Adjusted for: age, race/ethnicity, site, MENOPAUSAL STATUS, education, smoking , BMI, Body Mass 
Index; LDL-C  and hormone use 
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Table 6-4 Association of metabolic syndrome with carotid plaque in middle-aged women 
 IDF            NCEP-ATP III    WHO 
OR 95% CI AUC OR 95% CI AUC OR 95% CI AUC
All Women 
Unadjusted 1.61 (1.30, 2.01)      0.554 1.68 (1.35, 2.10) 0.557 1.69 (1.27, 2.24) 0.535 
Adjusted 1.70 (1.30, 2.18)      0.661 1.71 (1.31, 2.23) 0.660 1.98 (1.46, 2.75) 0.648 
No DM 
Unadjusted 1.54 (1.20, 1.97)      0.543 1.60 (1.24, 2.06) 0.545 --          -- -- 
Adjusted 1.57 (1.18, 2.08)      0.659 1.61 (1.20, 2.17) 0.661 --          -- -- 
* p<.0001; Carotid IMT, Carotid Intima-Media Thickness; IDF, International Diabetes Federation; NCEP-ATP, National Cholesterol of Education Program’s Adult Treatment
Panel III; WHO, World Health Organization; DM, Diabetes Mellitus; Adjusted for: Adjusted for: age, race/ethnicity, site, MENOPAUSAL STATUS, education, smoking , BMI, 
Body Mass Index; LDL-C  and hormone use 
63 
Table 6-5 Association of Individual components of metabolic syndrome with Carotid IMT in middle-aged women 
 IDF            NCEP-ATP III    WHO 
β(SE) P β(SE) P β(SE) P 
Hypertension 0.0273 (0.007) <.0001 0.0276(0.007) <.0001 0.0293(0.006) <.0001 
HDL-c -0.0008 (0.008) 0.9122 -0.0003(0.008) 0.9647 0.0172(0.016) 0.2977 
Glucose 0.0264 (0.007) 0.0002 0.0272(0.007) 0.0001 0.0211(0.008) 0.0098 
WC 0.0293 (0.009) 0.0009 0.0182(0.008) 0.0330 --- --- 
Triglycerides 0.00858 (0.008) 0.2911 0.0090(0.0081) 0.2684 0.0096(0.008) 0.2271 
BMI --- --- --- --- 0.0139(0.008) 0.0848 
* p<.0001; Carotid IMT, BP, Blood Pressure; WC, waist Circumference; Carotid Intima-Media Thickness; IDF, International Diabetes Federation; NCEP-ATP, National
Cholesterol of Education Program’s Adult Treatment Panel III; WHO, World Health Organization; Adjusted for: age, race/ethnicity, site, MENOPAUSAL STATUS, education, 
smoking , BMI, Body Mass Index; LDL-C  and hormone use 
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Table 6-6 Association of Individual components of metabolic syndrome with Carotid plaque in middle-aged women 
 IDF            NCEP-ATP III    WHO 
OR 95% CI  P OR 95% CI P OR 95% CI P 
Hypertension 1.65 (1.28, 2.13) 0.0001 1.62 (1.26, 2.09) 0.0002 1.75 (1.36, 2.25) <.0001 
HDL-C 1.30 (0.97, 1.73) 0.0841 1.27 (0.95, 1.69) 0.1063 1.60 (0.84, 2.98) 0.1607 
Glucose 1.48 (1.14, 1.95) 0.0035 1.48 (1.13, 1.93) 0.0043 1.32 (1.05, 1.98) 0.0235 
WC 1.01 (0.72, 1.42) 0.9441 1.27 (0.91, 1.75) 0.1527 --- --- 
Triglycerides 1.11 (0.82, 1.51) 0.4919 1.09 (0.80, 1.48) 0.5794 1.13 (0.84, 1.53) 0.4612 
BMI --- --- --- --- --- --- 1.40 (1.03, 1.90) 0.0319 
 BP, Blood Pressure; WC, waist Circumference; OR, odds ratio; CI, Confidence interval; P, p-value; Carotid IMT, Carotid Intima-Media Thickness; IDF, International Diabetes 
Federation; NCEP-ATP, National Cholesterol of Education Program’s Adult Treatment Panel III; WHO, World Health Organization; Adjusted for: age, race/ethnicity, site, 
MENOPAUSAL STATUS, education, smoking , BMI, Body Mass Index; LDL-C  and hormone use 
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Figure 6-1 The flowchart of participants included in this study 
Baseline SWAN Study population 
   Source (N=3302) 
Clinic Exams (Subclinical 
measures) 
(N= 1552) 
Visit 12 (N=2399) 
California UCLA site did 
not participate in 
Subclinical measures 
protocol 
Participants with IMT data 
(N=1507) 
66 participants had missing 
MetS status 
Participants with no IMT 
data 
(N=45) 
Final sample size: 1441 
IDF: Yes/No (499/942) 
ATP III:  Yes/No (464/977) 
WHO:  Yes/No (229/1212) 
Yes No 
66 
 
 
 
 
 
 
Figure 6-2 Prevalence of Metabolic Syndrome by definitions used in the study 
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Figure 6-3 Area under receiver-operator characteristic curve by metabolic syndrome definition 
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7.1 ABSTRACT 
 
Background and Objective: The metabolic syndrome (MetS) is linked to higher risk of 
cardiovascular disease (CVD) events, including stroke.  However, few studies have assessed 
MetS and maladaptive remodeling in relation to subclinical CVD.  The aim of this study was to 
examine whether MetS was associated with maladaptive remodeling of the common carotid 
artery, and if the association was independent of select inflammation, metabolic and 
hemodynamic factors. 
Methods: Participants from 6 sites of the Study of Women’s Health Across the Nation (SWAN) 
free of diabetics and who had B-mode ultrasound images at the 12th annual visit were analyzed.  
Women were classified as having MetS if they met the criteria defined by National Cholesterol 
Education Program Adults Treatment Panel III (NCEP-ATP III).   Multivariable linear 
regression was used to investigate the association between the presence of MetS and carotid 
remodeling while adjusting for potential confounders. 
Results:  MetS was significantly and positively associated with LD (β (95 % confidence 
interval)), 0.218 mm (0.149, 0.288)), AD (0.281 mm (0.201, 0.362)), IMT (0.032 mm (0.017, 
0.046)), CWT (5.48 kPa (4.16, 6.79)) and CWS (4.14 kPa (2.14, 6.13)) after adjustment for age, 
height, education, site, use of hormone therapy, menopausal status, low-density lipoprotein-
cholesterol and smoking. These associations were slightly lessened when inflammation, 
metabolic and hemodynamic variables were further adjusted for. The Hispanic by MetS 
interaction term was significantly associated with IMT.  The Black by MetS interaction was 
negatively associated with CWT.  Both Black and Hispanic ethnicities by MetS interaction terms 
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were negatively associated with CWS after adjustment for inflammatory, metabolic and 
hemodynamic factors. 
Conclusion: The presence of MetS is associated with maladaptive remodeling of the common 
carotid artery in non-diabetic middle-aged women independent of select inflammatory, 
metabolic, and hemodynamic risk factors.  Different patterns of remodeling were observed by 
race/ethnicity, and how these patterns of remodeling could potentially be related to the variation 
in risk of stroke warrant further examination. 
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 7.2 INTRODUCTION 
 
The presence of metabolic syndrome (MetS), defined as a cluster of risk factors including 
central obesity, dyslipidemia, elevated blood pressure and impaired glucose, is associated with 
incident ischemic stroke [186-188].  While the association between MetS and the risk of stroke is 
not clearly understood, it has been postulated that both structural and functional arterial changes 
such as the remodeling of large arteries located in the head and neck may play an important role 
in this association [189], however, there is paucity of data on the role of MetS on arterial 
remodeling (AR). 
Arterial remodeling occurs in response to inflammatory, metabolic, and hemodynamic 
alterations within the arterial environment [189, 190] and is considered  to occur naturally with 
aging.  Early arterial remodeling is significantly associated with hemodynamic changes, as well 
as cardiovascular morbidity and mortality [118].  Arterial remodeling consists of intimal-medial 
arterial thickening or dilation.  These processes can be evaluated non-invasively by using 
ultrasound to measure intima-media thickness (IMT) [191] and adventitial diameter (AD), 
respectively, of the common carotid artery.   Thicker IMT and wider AD have been shown to be 
risk factors for overt cardiovascular disease (CVD) and in particular, incident stroke[192].  
Furthermore, AR that occurs in concert with increases in circumferential wall tension (CWT) and 
circumferential wall stress (CWS) is considered maladaptive [189, 193].  Maladaptive AR is also 
associated with the risk of stroke, as evidenced by higher carotid CWT among patients who have 
had stroke [194]. 
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The association between MetS and carotid artery remodeling has been investigated in 
population-based studies.   Several epidemiological studies have reported an association between 
MetS and carotid artery remodeling in non-diabetic individuals [189], in young to middle-aged 
women [152], and in older adults independent of traditional CVD risk factors [163].  However, 
few studies have sought to characterize the association between MetS and arterial remodeling in 
combination with CWT and CWS.  Moreover, the published findings to date on MetS and 
carotid remodeling are limited to small samples of primarily white study participants.  Whether 
or not the MetS and common carotid artery remodeling relationship is applicable to women of 
older middle-aged and other ethnicities needs to be studied further. 
To address several of the gaps, our study examined the relationship between MetS and 
common carotid artery remodeling as measured by lumen diameter, AD, carotid IMT, CWT, 
CWS and the associated pattern of remodeling in a cohort of older middle-aged women of mixed 
races/ethnicities.  Furthermore, we assessed the role of inflammatory, metabolic and 
hemodynamic factors on the relationship between MetS and common carotid artery remodeling 
because the effect of these factors on the association between MetS and common carotid artery 
parameters have not been fully established.  Finally, we examined the relationship between 
race/ethnicity, MetS, and common carotid artery remodeling to evaluate differential effect by 
race/ethnicity via interactions between MetS and racial/ethnic groups. 
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7.3 METHODS 
 
7.3.1 Study Population 
 
The study sample consisted of women enrolled in the Study of Women’s Health Across 
the Nation (SWAN) who were pre/peri-menopausal or postmenopausal by their 12th follow-up 
visit.  SWAN is a multiethnic, community-based, longitudinal cohort of the natural history of 
3302 women enrolled at 7 sites throughout the United States (Boston, Massachusetts; Chicago, 
Illinois; Detroit, Michigan; Los Angeles, California; Oakland, California; Newark, New Jersey; 
and Pittsburgh, Pennsylvania).   The cohort at baseline was composed of White, Black, Chinese, 
Japanese and Hispanic women, aged 42 to 52 years, who had an intact uterus and at least one 
ovary, had at least one menstrual period in the preceding 3 months, had not used sex steroid 
hormone therapy in the preceding 3 months and were not pregnant.  Of the initial 3302 women at 
baseline, 2399 participants were seen at 12th visit, and 1552 (64.7%) underwent a carotid artery 
ultrasound examination as part of the study visit.  The University of California at Los Angeles 
site did not participate in the carotid ultrasound protocol and is therefore not included in this 
analysis.   Among participants who participated in the carotid ultrasound protocol, 45 women 
were removed from the analysis due to missing IMT data.  An additional 60 participants were 
excluded due to missing data pertaining to MetS criteria, and 193 diabetic participants were 
excluded because of compromised arterial function in type 2 diabetics, leaving a final sample 
size of 1254 (80.8%) participants (Figure 7-1).   The institutional review board at each site 
approved the protocol and all women provided written informed consent. 
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7.3.2 Assessment of cardiovascular and metabolic risk factors 
 
All study participants underwent annual or biannual study visits consisting of 
interviewer-administered questionnaires to ascertain medication use, medical history, lifestyle 
characteristics and menopausal status, physical measures, and a fasting blood draw and for 
assessment of cardiovascular risk factors and reproductive hormone levels.  Race or ethnicity 
was self-reported.    
 
Blood pressure was measured in the right arm, while participants were seated with feet 
flat on floor following at least 5 minutes of sitting quietly before measurements were taken.  A 
standard mercury sphygmomanometer was used to measure systolic and diastolic pressures at 
first and fifth korotkoff sounds.  The average of two sequential readings was used in the 
analyses.  Pulse pressure was defined as difference between systolic and diastolic blood pressure.  
Height was measured without shoes using a stadiometer.  Weight was measured without shoes, 
and with light indoor clothing using calibrated scales. Waist circumference was measured with 
participants in light undergarments.   
 
Lipids, glucose and insulin were measured on a Siemens ADVIA 2400 automated 
chemistry analyzer utilizing Siemens ADVIA chemistry system reagents (Siemens Healthcare 
Diagnostics, Deerfield IL) at the University of Michigan Pathology Laboratory, a Clinical 
Laboratory Improvements Amendments (CLIA) certified and accredited laboratory.  
Triglycerides, high-density lipoprotein cholesterol (HDL-C) and directly-measured low density 
lipoprotein cholesterol (LDL-C) [174] were analyzed using a coupled enzymatic methods that 
utilized lipase, glycerol kinase, glycerol-3-phosphate oxidase (G3PO), and peroxidase (for 
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triglycerides) and cholesterol esterase, cholesterol oxidase, and peroxidase (for HDL-C and 
direct LDL-C).   Serum insulin was measured by a two-site sandwich immunoassay using direct 
chemiluminescent technology that uses constant amounts of two antibodies.  High sensitivity C-
reactive protein (CRP) levels were measured using an ultra-sensitive rate immunonephelometric 
method (BN 100, Dade-Behring, Marburg, Germany). Adiponectin was measured via the 
quantitative sandwich enzyme immunoassay technique.  Glucose was measured using a two-step 
enzymatic reaction that utilized hexokinase and glucose-6-phosphate dehydrogenase (G6PDH) 
enzymes.  Diabetes was defined as either fasting glucose ≥ 126 mg/dL, diagnosis of diabetes by a 
physician or use of anti-diabetic medications.  
 
7.3.3 NCEP-ATP III metabolic syndrome definition 
 
The NCEP-ATP III criterion was used to identify MetS. This definition consists of 
meeting at least three of the following five factors: central obesity (waist circumference > 102 
cm for men, > 88 cm for women), raised triglycerides ( ≥ 150 mg/dL), elevated blood pressure ( 
systolic blood pressure ≥130 mmHg / diastolic blood pressure ≥ 85 or use of anti-hypertensive 
medications), fasting plasma glucose ( ≥110 mg/dL) and reduced HDL cholesterol ( < 40 mg/dL 
for men,  < 50 mg/dL for women) [175]. An individual with three or more of the above factors 
was classified as having MetS.  
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7.3.4 Carotid Arterial Properties 
 
At each site, centrally trained and certified sonographers obtained carotid ultrasound 
images using a Terason t3000 Ultrasound System (Teratech Corp, Burlington, MA) equipped 
with a variable frequency 5-12 MHz linear array transducer.  Two digitized images for later 
reading by 2 trained readers at the SWAN Ultrasound Reading Center (University of Pittsburgh 
Ultrasound Research Lab) were obtained for each of the left and right distal common carotid 
artery (CCA).  From each of these 4 images, using the Artery Measurement System (AMS) semi-
automated edge detection software [178], near and far wall CCA intima-media thickness (IMT) 
measures were obtained by electronically tracing the lumen-intima interface and the media-
adventitia interface across a 1-cm segment proximal to the carotid bulb.  The average and 
maximal values were recorded for each image, with the mean of the average and maximal 
readings of all images used in analyses. Common carotid artery (CCA) inter-adventitial 
diameters were measured directly as the distance from the adventitial-medial interface on the 
near wall to the medial-adventitial interface on the far wall at end-diastole across the same CCA 
segments used for IMT measurement.  Lumen diameter (LD) was directly measured, and defined 
as the distance from the intima-lumen interface of the near wall to the lumen-intima interface of 
the far wall.  Mean circumferential wall tension (CWT) and circumferential wall stress (CWS) 
were calculated according to Laplace’s law[194].  Mean CWS and CWT were calculated as 
CWT (kPa) = MAP (LD/2) and CWS (kPa) = mean CWT/IMT [189], where MAP is the mean 
arterial pressure.  MAP was approximated as [(2* diastolic blood pressure) + systolic blood 
pressure]/3. Reproducibility of IMT measures was good to excellent with an intraclass 
correlation coefficient between sonographers of ≥ 0.77, and between readers of > 0.90. The 
scanning and reading protocols have been used in numerous studies [180, 181, 195].  
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7.3.5 Statistical analyses 
 
Demographic characteristics, cardiovascular disease risk factors, and measures of carotid 
artery properties were compared between participants with and without MetS using the chi-
square test for categorical variables, and either t-tests or Wilcoxon test for continuous variables 
depending on the distribution of the variable.   
Multivariable linear regression was used to examine the relationship between MetS and 
carotid artery properties, as measured by lumen diameter, adventitial diameter, carotid IMT, 
mean circumferential wall stress and circumferential wall tension.  A series of models were fit:  
model 1 adjusted for age, height, education, site, hormone use, menopausal status, LDL-
cholesterol and smoking.  These variables were controlled for based on previous studies, as well 
as the design of the SWAN Study.   To assess the additional effect of inflammation on the 
association between MetS and common carotid artery parameters, high sensitivity C- reactive 
protein (CRP), a non-specific marker of inflammation, was added to model 1.  The effect of the 
metabolic factor adiponectin and the hemodynamic factor pulse pressure were also assessed in 
relation to MetS and common carotid artery parameters by adding each to model 1.  
The relationship between MetS and common carotid artery remodeling was assessed 
whether it differed by race and ethnicity.  The White participants were used as the reference 
group.  To test whether remodeling differed by race/ethnicity and MetS, interaction terms were 
included to the models specified above that also included the main effects for MetS and 
race/ethnicity.  In the regression model, the association between MetS and carotid properties was 
reported as coefficient (betas) along with the 95 % confidence intervals.  Regression assumptions 
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were assessed in each model fit.   A two-sided p-value (<0.05) was considered statistically 
significant. 
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 7.4 RESULTS 
 
Clinical characteristics by MetS status 
Selected clinical characteristics measured at the 12th study visit according to the presence 
or absence of MetS is described on Table 7-1.  The prevalence of MetS was 25.7% with the 
prevalence of MetS among the racial group as follows: Blacks (31.8%), White (24.4%), Chinese 
(13.6%) and Hispanic (36.7%), p<0.001.  Higher levels of hsCRP and fasting insulin were 
observed among participants with MetS.   Participants without MetS had higher mean total 
cholesterol levels, were less likely to report use of lipid modifying medications and also had 
higher mean adiponectin levels than those with MetS. 
Participants with MetS had greater mean carotid IMT, LD and AD compared to 
participants without MetS (Table 7-2).  Furthermore, participants with MetS had greater mean 
CWS and CWT compared to participants without MetS. 
 
MetS and Arterial remodeling 
MetS was significantly associated with both LD and AD even after adjustment for age, 
height, education, site, hormone use, menopausal status, low-density lipoprotein-cholesterol and 
smoking (Table 7-3, model 1).  With the inclusion of the inflammatory marker hsCRP, both LD 
and AD remained significantly associated with MetS, but the strength of the associations slightly 
lessened (Table 7-3, model 2).  Further adjustment for the metabolic factor adiponectin and the 
hemodynamic factor pulse pressure did not change the relationship between MetS and both LD 
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and AD (Table 7-3, model 3 and 4).   Similar to measures of lumen diameter, MetS was 
significantly associated with carotid IMT after adjustment for age, height, education, site, 
hormone use and menopausal status, low-density lipoprotein-cholesterol and smoking (Table 7-
3, model 1).   After adjusting individually for inflammatory, metabolic, and hemodynamic risk 
factors, the presence of MetS was significantly and positively associated with carotid IMT (Table 
7-3, model 2-4).   The presence of MetS was significantly associated with higher mean CWT and 
CWS after controlling for age, height, education, site, hormone use and menopausal status, low-
density lipoprotein-cholesterol and smoking (Table 7-3, model 1).  Adjusting for hsCRP did not 
alter the association between MetS and mean CWT and CWS (Table 7-3, model 2).  Again, 
adjusting for metabolic and hemodynamic factors did not change the associations between MetS 
and mean CWT and CWS (Table 7-3, Model 3 and 4). 
Mets and carotid arterial properties by race/ethnicity 
To assess a differential effect of race/ethnicity and metabolic status on carotid 
remodeling, the overall effect of racial/ethnic, main effects and interaction terms for each 
racial/ethnic group were tested.  The overall effect of race was significantly associated with LD, 
AD, IMT, CWT and CWS after adjusting for potential confounders. The main effects of Black 
and Chinese ethnicities were significantly associated with LD (Table 7-4).   Only the main effect 
of Black ethnicity was significantly associated with AD (Table 7-5), carotid IMT (Table 7-6), 
CWT (Table 7-7) and CWS (Table 7-8) after adjusting for potential confounders. 
 None of the race and ethnicity by MetS interaction terms was significant with respect to 
LD (Table 7-4).   However, the interaction term for Hispanic participants by MetS was close to 
being significantly associated with AD after adjustment for pulse pressure (Table 7-4, model 4). 
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The Hispanic by MetS interaction term was significantly associated with carotid IMT after 
controlling for age, height, education, site, hormone use, menopausal status, low-density 
lipoprotein-cholesterol and smoking (Table 7-6, model 1).   Including hsCRP in the model, there 
was a marginal association between Hispanic by MetS interaction term and carotid IMT (Table 
7-6, model 2).   The Hispanic by MetS interaction term remained significantly associated with 
carotid IMT after further adjustment for metabolic and hemodynamic factors (Table 7-6, model 3 
and 4). 
The Black by MetS interaction term was negatively associated with circumferential wall 
tension (CWT) and independent of inflammatory, metabolic and hemodynamics factors (Table 7-
7).  Similar patterns were observed for the interaction terms between Hispanic ethnicity and 
MetS but statistical significance was not reached.  Both Black and Hispanic ethnicities by MetS 
interaction terms were negatively associated with circumferential wall stress (CWS) independent 
of inflammatory, metabolic and hemodynamic factors.  In race-specific model, we found 
variations of association between MetS and IMT.   Among Chinese, Black ethnicities, significant 
associations between MetS and IMT were observed independent of   metabolic and 
hemodynamic factors.  No significant association was observed between MetS and IMT among 
Whites while adjusting for inflammatory, metabolic and hemodynamic factors.  CWT and CWS 
were significantly associated with MetS in each of the race-specific model for Black, Whites, 
Chinese and Hispanic ethnicities independent of inflammatory and metabolic factors.  
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7.5 DISCUSSION 
 
This study assessed the association between MetS and remodeling of the common carotid 
artery among non-diabetic older middle-aged women.  Our findings showed that MetS is 
significantly associated with maladaptive remodeling of the common carotid artery as indicated 
by greater mean adventitial diameter, lumen diameter and carotid IMT.  Moreover, an outward 
pattern of remodeling was observed as evidenced by greater mean circumferential wall tension 
and circumferential wall stress in women with MetS.  Our findings also indicated that the 
associations between MetS and carotid artery remodeling are independent of inflammatory, 
hemodynamic, and metabolic risk factors.  Finally, we observed differential maladaptive 
remodeling patterns of the common carotid artery with MetS status by race/ethnicity.  
Specifically, Black and Hispanic women with MetS experienced more extreme remodeling of the 
common carotid artery than their White counterparts.   
In this study, we assessed the impact of inflammatory, metabolic and hemodynamic 
factors on the relationship between MetS and carotid artery remodeling.  While the roles of these 
factors on the relationship between MetS and carotid artery remodeling are still not clear [196-
198], we found a significant difference in the non-specific marker of inflammation hsCRP 
among those with MetS compared to those without MetS.  However, hsCRP did not explain the 
association between MetS and carotid artery remodeling.   In our study, we also observed lower 
levels of adiponectin among participants with MetS compared to those without MetS, and yet, 
the association between MetS and carotid artery remodeling was not explained by hypo-
adiponectinemia.  Hypoadiponectinemia has been shown to be associated with ischemic stroke 
[199, 200], and in line with this association, it has been suggested that adiponectin levels be 
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incorporated in the criteria that define MetS [196].  However we found no evidence to support 
such a proposition.   Furthermore, the assessment of the hemodynamic factor pulse pressure did 
not explain the relationship between MetS and carotid artery remodeling, although the strength 
of the association was lessened slightly with the addition of pulse pressure to the models.  These 
findings suggest that there are other potential factors at play in the association between MetS and 
carotid artery remodeling other than those that have been explored in this study. 
The findings from our study are in an agreement with what others have reported 
regarding the association between MetS and carotid artery remodeling [152, 163, 189].   In a 
French study, Empana et al reported significant association between MetS and carotid artery 
structure along with the outward pattern of remodeling of the carotid artery [163].   Iannuzzi et al 
also observed a significant association between MetS and carotid remodeling in middle-aged 
women, as well as an outward pattern of remodeling [152].  However, none of these two 
previous studies evaluated either CWT or CWS, which are measures used to determine whether 
or not observed remodeling patterns are maladaptive.  In a small study of older white adults, 
Beijers et al reported that MetS was associated with maladaptive remodeling of the carotid artery 
as depicted by changes in carotid artery measures along with increases in mean CWT and CWS 
(4).   As an extension to the findings of Beijers et al, we found significant associations between 
MetS and carotid IMT independent of inflammatory, hemodynamic and metabolic factors, along 
with significant changes in CWT and CWS in a multiethnic study population. 
The findings from this study showed that not only was race/ethnicity associated with 
measures of remodeling of the carotid artery independent of MetS but that there was a 
differential effect by race/ethnicity and MetS status.  We observed significant interactions 
between Hispanic ethnicity by MetS and carotid IMT independent of confounding factors 
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including age, height, education, site, hormone use, menopausal status, low-density lipoprotein-
cholesterol and smoking, as well as select inflammatory, metabolic and hemodynamic factors.  
Hispanic ethnicity by MetS was marginally associated with AD.   A significant association was 
observed between Black ethnicity and CWT.   We also observed significant interaction terms by 
Black and Hispanic ethnicities on the association between MetS and CWS independent of the 
inflammatory, metabolic and hemodynamic factors evaluated in our analyses.  Taken together, 
these findings point to a pattern of maladaptive remodeling that differed by race/ethnicity, which 
is important because  there are evidence that it is associated with greater risk of stroke[194].   
The study participants are in midlife, which is very important phase of life for women, where 
changes in lipids [201] and vascular measures such as IMT [202]are reported to occur.  Given 
these changes that are known to occur in midlife, the variations in associations observed in this 
study clearly have clinical implication in light of the known differences in morbidity and 
mortality in CVD. 
Several epidemiological studies have linked the MetS and vascular remodeling, as well as 
greater risk for incidence of stroke.  Data from the National Health and Nutrition Examination 
Survey (NHANES) established a significant association between MetS and ischemic stroke [77], 
as well as a higher number of prevalent vascular risk factors among ethnic women as compared 
to white women[203].  Several prospective studies have also shown a link between MetS and 
stroke [186, 204].  In a multiethnic Northern Manhattan Study (NOMAS) cohort, Boden-Albala 
et al [205] reported  that the presence of MetS was strongly associated with vascular disease  and 
stroke in women, and that the association  was strongest among Hispanic participants.  In the 
Cardiovascular Health Study (CHS) cohort, O’Leary et al showed that increases in carotid IMT 
were directly associated with greater risk of stroke in older adults without a history of CVD 
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[206].  Bots et al reported a significant association between carotid IMT and stroke in the 
Rotterdam Elderly Study [191].  In spite of the findings from these studies, there were limitations 
that our current study sought to address.  CHS did not assess the effect of race and ethnicity on 
the association between risk of stroke and increases on carotid IMT, as well as evaluated 
measures to characterize the extent of the carotid remodeling. The Rotterdam Elderly Study 
included participants with symptomatic cardiovascular disease and the authors concluded that 
incorporating such participants affected the magnitude of the association between carotid 
remodeling and stroke.  In our study, a potential explanation for the differential pattern of 
maladaptive remodeling of the carotid artery by race/ethnicity could be due largely to some 
unmeasured risk factors.  There are ethnic and racial variations in some subclinical CVD 
measures [207, 208] .  Black ethnicity is reported to have a greater mean IMT compared to South 
Asians [207],  and non-Hispanic White [209]  when CVD risk factors are adjusted for.  In vein of 
these ethnic and racial variations, it remains to be seen if the ethnic comparisons in this study are 
valid or not; however, if  appropriate set of covariates are adjusted for then the comparisons in 
this study should be deemed to  be right.  Given the entirety of the evidence, it is possible that 
variations in stroke risk could be as a result of the underlying vascular risk factors and their 
association with surrogate measures of subclinical atherosclerosis all of which vary by the 
race/ethnicity.  
The current study has some strengths as well as limitations.  This is the first study to 
assess carotid artery remodeling in a multi-ethnic cohort focused on examining the association 
between MetS and carotid remodeling in non-diabetic older middle-aged women.  As a cross-
sectional study, inferences regarding causality must be made with caution.  There was paucity of 
data in Hispanic ethnicity therefore the importance of comparisons made in this study must be 
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carefully interpreted. No three dimensional images of the carotid artery image were made, 
therefore vascular measurements such as CWT and CWS might have either underestimated or 
overestimated the association between MetS and carotid artery remodeling.   
  In conclusion, the presence of MetS is associated with maladaptive remodeling of the 
common carotid artery in non-diabetic older middle-aged women independent of select 
inflammatory, metabolic, and hemodynamic risk factors.   Different patterns of remodeling were 
observed by race/ethnicity, and how these patterns of remodeling could potentially be related to 
the variation in risk of stroke warrant further examination.  The findings suggest that targeting 
metabolic syndrome in midlife women would subsequently help to prevent CVD among 
multiethnic women. 
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7.6 TABLES AND FIGURES 
 
Table 7-1 Baseline characteristics according to metabolic syndrome status 
  Metabolic Syndrome  
Characteristics Absent (N=932) Present(N=322) P value 
Age(years) 59.6±2.7 59.6±2.7 0.50 
Race (n, %)    
Black 247(26.5) 115(35.7) <.0001 
White 501(53.8) 162(50.3)  
Chinese 146(15.7) 23(7.1)  
Hispanic 38(4.1) 22(6.8)  
MetS Traits    
Systolic blood pressure(mm Hg) 118.8±15.8 127.7±16.0 --- 
Diastolic blood pressure(mm Hg) 73.3±9.8 77.1± 9.8 --- 
Antihypertensive medication use n 
(%) 
233(25.0) 208(64.6) --- 
HDL-cholesterol (mg/dl) 67.5±15.6 51.4±11.9 --- 
Triglycerides(mg/dl) 90(68-116) 145.5(107-190) --- 
Fasting glucose(mg/dl) 89(84-95) 101(93-110) --- 
Waist(cm) 86.9±13.2 103.4±13.7 --- 
Other characteristics    
Smoking n (%) 61(6.7) 44(13.8) <.0001 
BMI(kg/m2 ) 27.7±6.3 34.1±6.5 <.0001 
Total cholesterol (mg/dl) 210.1±35.9 203.5±38.7 <.0001 
LDL-cholesterol(mg/dl) 123.3±29.0 121.2±31.4 <.0001 
Treatment with lipid-lowering 
medications n (%) 
180(19.3) 132(41.0) <.0001 
Fasting  Insulin (uIU /ml) 7.1(4.8-11.0) 15.6(11.3-22.7) <0.001 
HOMAIR 1.6(1.02-2.48) 3.88(1.88-5.82) <.0001 
Heart rate(bpm) 66.0±8.2 68.6±9.7 0.0001 
Hs-CRP(mg/l) 1.16(0.47-1.16) 3.14(1.26-7.27) <.0001 
Adiponectin (mg/mL) 15.4±9.7 8.4±5.2 <.0001 
Hormone use n (%) 46(4.9) 15(4.7) 0.84 
Data are presented as mean ± s.d or median (interquartile range); BMI, body mass index; HDL, high-density lipoprotein; HOMAIR , homeostasis model assessment for insulin 
resistance; LDL, low-density lipoprotein; MetS, metabolic syndrome; WHR, waist-to-hip ratio; Hs-CRP, high sensitivity C-reactive protein. 
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Table 7-2 Carotid arterial properties according to metabolic syndrome status 
 Carotid Arterial Properties Metabolic syndrome 
  Absent               Present 
   (n=932)              (n=322) 
P value 
Mean Adventitial diameter (mm) 7.07 ±0.61           7.39±0.66        <.0001 
Mean Intima-media thickness (mm) 0.77 ±0.11           0.82±0.13 <.0001 
Mean Lumen diameter (mm) 5.5±0.53                5.8±0.56 <.0001 
Mean circumferential wall tension (kPa) 32.6±5.5               36.1±5.6 <.0001 
Mean circumferential wall stress (kPa) 42.7±7.9               45.0±8.5 <.0001 
 Results are expressed as means ± s.d; adjusted for age, race and site; mm, millimeter 
89 
 Table 7-3 Carotid remodeling according to the presence or absence of MetS 
 
Model LD(mm) AD(mm) IMT(mm) CWT(kPa) CWS(kPa) 
  β                       95% CI  β                         95% CI  β                     95% CI  β                   95% CI  β              95% CI 
1 0.218             0.149,  0.288* 0.281          0.201,   0.362* 0.032           0.017,  0.046*  5.48           4.16,  6.79* 4.14          2.14, 6.13* 
2 0.206             0.132,  0.279* 0.258          0.173,   0.343*               0.026           0.011,   0.042* 5.20           3.81,  6.59* 4.30          2.21, 6.39* 
3 0.200             0.127, 0.273* 0.255          0.171,   0.339* 0.028           0.013,  0.043* 4.99            3.60,  6.37* 3.87         1.77,  5.97* 
4 0.188             0.119,  0.257* 0.236          0.157,  0.315* 0.024          0.009,  0.0381* 4.10            2.89,  5.31* 3.12           1.15, 5.09* 
Results are expressed as regression coefficients (beta) and respective 95% CI. The regression coefficient beta indicates the difference in arterial property (in units) between 
individuals with vs. without MetS. LDL-c, Low-density lipoprotein cholesterol; hsCRP, high sensitivity C - reactive protein; ln, logarithm; *P<0.001. 
Model1, adjusted for age, height, education, site, hormone use, menopausal status, LDL-cholesterol + smoking  
Model2, adjusted for model 1 + In –hsCRP 
Model3, adjusted for model 1 + Adiponectin 
Model4, adjusted for model 1 + pulse pressure 
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Table 7-4  Carotid remodeling according to the presence or absence of MetS by race/ethnicity: LD 
 
  LD   
 Model 1 Model 2 Model  3 Model 4 
  β (SE)               P  β  (SE)               P   β   (SE)          P β   (SE)           P 
MetS 0.23(0.05)      <.0001 0.19(0.05)     0.0002 0.22(0.05)     <.0001 0.19(0.05)   <.0001 
Ethnicity     
Black 0.15(0.04)     0.0011 0.11(0.05)     0.0208 0.13(0.05)     0.0050 0.11(0.04)    0.0122 
Chinese 0.25(0.07)    0.0002 0.25(0.07)      0.0006 0.25(0.07)       0.0002 0.26(0.063)   <.0001 
Hispanic -0.04(0.12)    0.7372 -0.07(0.13)    0.5904 -0.049(0.12)   0.6917 -0.049(0.12)   0.6812 
Black*MetS -0.038(0.08)   0.0767 -0.001(0.08)  0.9851 -0.028(0.08)  0.7139 -0.027(0.08)   0.7167 
Chinese*MetS -0.067(0.13)  0.1298 -0.056(0.13)   0.6712 -0.062(0.13)  0.6310 -0.07(0.13)     0.5888 
Hispanic*MetS  0.14(0.15)      0.1490  0.19(0.15)      0.2122 0.15(0.14)     0.3181 0.17(0.14)      0.2354 
Results are expressed as regression coefficients (beta) and respective standard error; p-value. The regression coefficient beta indicates the difference in arterial property (in units) 
between individuals with vs without MetS; LD, Lumen Diameter; LDL-c, Low-density lipoprotein cholesterol; hsCRP, high sensitivity C - reactive protein; ln, logarithm; 
Reference group: white women 
Model1, adjusted for age, height, education, site, hormone use, menopausal status, LDL-cholesterol, smoking; 
Model2, adjusted for model 1 + In – hsCRP 
Model3, adjusted for model 1 + Adiponectin 
Model4, adjusted for model 1 + pulse pressure 
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Table 7-5 Carotid remodeling according to the presence or absence of MetS by race/ethnicity: AD 
 
  AD   
 Model 1 Model 2 Model 3 Model 4 
 β (SE)               P β  (SE)                P β (SE)                P β   (SE)            P 
MetS 0.26(0.06)   <.0001 0.22(0.06)       0.0002 0.25(0.06)  <.0001 0.21(0.05)    0.0002 
Ethnicity     
Black 0.22(0.05)   <.0001 0.19(0.05)      0.0006 0.19(0.05)    0.0002 0.17(0.05)      0.0010 
Chinese 0.27(0.08)   0.0004 0.27(0.08)     0.0010 0.27(0.08)    0.0006 0.29(0.08)      0.0001 
Hispanic -0.06(0.14)  0.6991 -0.09(0.15)     0.5617 -0.06(0.14)   0.6477 -0.07(0.14)    0.6094 
Black*MetS 0.004(0.09) 0.9669 0.023(0.09)   0.8014 0.008(0.08)  0.9258 0.020(0.09)  0.8170 
Chinese*MetS 0.026(0.15) 0.8610 0.030(0.15)   0.8426 0.032(0.15)  0.8291 0.025(0.15)   0.8648 
Hispanic*MetS 0.27(0.17)  0.1160 0.313(0.18)     0.0763 0.28(0.17)     0.1066 0.32(0.17)     0.0599 
Results are expressed as regression coefficients (beta) and respective standard error; p-value. The regression coefficient beta indicates the difference in arterial property (in units) 
between individuals with vs. without MetS; AD, Adventitial diameter; LDL-c, Low-density lipoprotein cholesterol; hsCRP, high sensitivity C - reactive protein, ln, logarithm; 
Reference group: white women 
Model1, adjusted for age, height, education, site, hormone use, menopausal status, LDL-cholesterol, smoking 
Model2, adjusted for model 1 + In – hsCRP 
Model3, adjusted for model 1 + Adiponectin 
Model4, adjusted for model 1 + pulse pressure 
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Table 7-6 Carotid remodeling according to the presence or absence of MetS by race/ethnicity: IMT 
 
   IMT  
 Model 1 Model 2 Model 3 Model 4 
 β (SE)                   P β  (SE)                  P β (SE)                  P β   (SE)                P 
MetS 0.016(0.01))    0.1101 0.014(0.01)   0.1934 -0.004(0.01)    0.7121 0.008(0.009)  0.4488 
Ethnicity     
Black 0.035(0.009)   0.0001 0.037(0.009)   <.0001 0.028(0.009)   0.0018 0.028(0.009)  0.0022 
Chinese 0.010(0.014)   0.4678 0.013(0.014)   0.3950 0.009(0.014)   0.4701 0.013(0.014)  0.3467 
Hispanic -0.007(0.03)  0.7905 -0.008(0.03)   0.7558 -0.014(0.03)    0.5832 -0.011(0.02)  0.6742 
Black*MetS 0.021(0.02)     0.1844 0.012(0.02)     0.4510 0.022(0.01)      0.1138 0.024(0.016)  0.1292 
Chinese*MetS 0.047(0.03)     0.0826 0.043(0.3)       0.1147 0.049(0.03)     0.0671 0.047(0.03)    0.0759 
Hispanic*MetS 0.064(0.03)     0.0394 0.061(0.03)     0.0566 0.062(0.3)        0.0443 0.071(0.3)      0.0196 
Results are expressed as regression coefficients (beta) and respective standard error, p-value. The regression coefficient beta indicates the difference in arterial property (in units) 
between individuals with vs. without MetS; IMT, Intima-media thickness; LDL-c, Low-density lipoprotein cholesterol; hsCRP, high sensitivity C - reactive protein, ln, logarithm; 
Reference group: white women 
 
Model1, adjusted for age, height, education, site, hormone use, menopausal status, LDL-cholesterol, smoking; 
Model2, adjusted for model 1 + In – hsCRP 
Model3, adjusted for model 1 + Adiponectin 
Model4, adjusted for model 1 + pulse pressure 
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Table 7-7 Carotid remodeling according to the presence or absence of MetS by race/ethnicity: CWT 
 
           CWT   
 Model 1 Model 2 Model 3 Model 4 
 β (SE)                    P β  (SE)                  P β  (SE)               P β (SE)                     P 
MetS 6.8(0.91)       <.0001 6.27(0.96)     <.0001 6.54(0.95)     <.0001 5.15(0.84)         <.0001 
Ethnicity     
Black 5.52(0.83)       <.0001 4.99(0.88)       <.0001 5.12(0.87)       <.0001 4.04(0.77)        <.0001 
Chinese 1.74(1.25)        0.1681 2.34(1.34)        0.0812 1.65(1.27)       0.1949 2.26(1.15)        0.0494 
Hispanic 1.69(2.32)       0.4655 0.62(2.42)       0.7986 1.49(2.32)       0.5207 1.09(1.94)         0.6057 
Black*MetS -4.09(1.45)      0.0048 -3.38(1.49)      0.0215 -3.81(1.46)     0.0092 -3.33(1.32)      0.0122 
Chinese*MetS 2.06(2.44)        0.3990 1.85(2.48)       0.4552 2.09(2.44)       0.3924 2.05(2.23)         0.3580 
Hispanic*MetS -3.38(2.79)       0.2279 -2.62(2.88)       0.3626 -3.37(2.80)     0.2288 -1.94(2.56)        0.4487 
Results are expressed as regression coefficients (beta) and respective standard error, p-value. The regression coefficient beta indicates the difference in arterial property (in units) 
between individuals with vs without MetS. CWT, Circumferential Wall Tension; LDL-c, Low-density lipoprotein cholesterol; hsCRP, high sensitivity C - reactive protein; ln, 
logarithm; Reference group: white women 
Model1, adjusted for age, height, education, site, hormone use, menopausal status, LDL-cholesterol, smoking; 
Model2, adjusted for model 1 + In – hsCRP 
Model3, adjusted for model 1 + Adiponectin 
Model4, adjusted for model 1 + pulse pressure 
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 Table 7-8 Carotid remodeling according to the presence or absence of MetS by race/ethnicity: CWS 
 
           CWS   
 Model 1 Model 2 Model 3 Model 4 
 β (SE)                     P β  (SE)                 P β  (SE)               P β (SE)                    P 
MetS 7.24(1.39)        <.0001 6.76(1.46)       <.0001 6.97(1.45)      <.0001 6.03(1.38)       <.0001 
Ethnicity     
Black 3.76(1.28)          0.0034 2.62(1.34)       0.0519 3.41(1.33)      0.0108 2.66(1.27)         0.0358 
Chinese 1.49(1.93)          0.4407 2.22(2.04)        0.2765 1.42(1.95)      0.4664 1.88(1.82)         0.3197 
Hispanic 2.69(3.55)          0.4499 1.16(3.67)        0.7521 2.53(3.56)     0.4782 2.24(3.48)         0.5205 
Black*MetS -7.24(2.21)         0.0011 -5.42(2.28)       0.0176 -6.69(2.24)    0.0028 -6.67(2.18)       0.0022 
Chinese*MetS -1.31(3.74)         0.7260 -1.36(3.77)      0.7192 -1.32(3.74)    0.7242 -1.31(3.67)       0.7203 
Hispanic*MetS -10.26(4.29)      0.0170 -8.64(4.38)      0.0488 -10.2(4.29)    0.0173 -9.19(4.21)       0.0294 
Results are expressed as regression coefficients (beta) and respective standard error; p-value. The regression coefficient beta indicates the difference in arterial property (in units) 
between individuals with vs without MetS. CWS, Circumferential Wall Stress; LDL-c, Low-density lipoprotein cholesterol; hsCRP, high sensitivity C - reactive protein, ln, 
logarithm; Reference group: white women 
 
Model1, adjusted for age, height, education, site, hormone use, menopausal status, LDL-cholesterol, smoking; 
Model2, adjusted for model 1 + In – hsCRP 
Model3, adjusted for model 1 + Adiponectin 
Model4, adjusted for model 1 + pulse pressure 
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Figure 7-1 The flowchart of participants included in this study 
Baseline SWAN Study population 
                   Source (N=3302) 
Clinic Exams (Subclinical 
measures) 
(N= 1552) 
Visit 12 (N=2399) 
California UCLA site did 
not participate in 
Subclinical measures 
protocol 
Participants with IMT data 
(N=1507) 
60 participants had missing 
MetS status 
 
Participants with no IMT 
data 
(N=45) 
 
Yes No 
Participants without Diabetes 
Final sample size: 1254 
ATP III: Yes/No (322/932) 
 
Participants with Diabetes 
   (N =193) 
 
Yes No 
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8.1 ABSTRACT 
 
Background:  Metabolic syndrome (MetS) is associated with a higher risk for cardiovascular 
disease (CVD) events, including stroke.  While the association between MetS and the risk of 
stroke is poorly understood; changes in structural and functional arteries parameters are posited 
to play a role in this association given the varying effects of MetS status changes. We aimed to 
examine changes in carotid artery structural and functional parameters in relation to changes in 
MetS status and its components in midlife women.  
 
Methods: Data for current study are from the Study of Women’s Across the Nation (SWAN) 
Heart Study, an ancillary study designed to examine natural history of subclinical atherosclerosis 
during the menopausal transition from two sites.  The Pittsburgh and Chicago sites both recruited 
and followed Black and White Women.   Baseline and follow-up visits occurred between 2001 
and 2004. Participants were classified as having MetS or not at baseline and follow-up visits if 
they met the criteria defined by International Diabetes Federation (IDF). Participants were then 
assigned into one of the 4 groups: never, incident, recovery and persistent. Generalized 
estimating equations (GEE) were used to assess differences in carotid parameters at baseline and 
at follow-up visits, and their changes over time between the four MetS groups.  All analyses 
were adjusted for age, education, smoking, LDL-c, cholesterol lowering medication, and 
menopausal status. 
 
Results:  At baseline and follow-up, the women in the persistent MetS group had larger mean 
IMT (β±SE: 0.76±0.12), and the recovery MetS group had larger mean AD (7.2±0.07), LD 
(5.6±0.67), CSA (15.2±2.4), CWT (34.1±4.4), CWS (53.3±7.8) as compared to other MetS 
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groups.  During the follow-up, the persistent MetS group experienced a steeper increase in 
carotid IMT compared to those who never developed MetS (0.02 versus 0.012 mm/y). The 
recovery MetS group showed a negative rate of change on LD (-0.1 versus 0.0 mm/y), whereas 
other MetS categories did not differ in comparison to the reference group.  CWT increased in 
both the incident (0.45 versus -0.3 kPa/y) and persistent (0.05 versus -0.3 kPa/y) MetS groups 
and decreased in the recovery MetS group (-1.55 versus -0.3 kPa/y) as compared to the never 
group. 
Conclusion: Midlife women with persistent MetS over the course of 2-years of follow-up were 
more likely to experience carotid artery remodeling compared to those who never developed 
MetS.  The reversibility of maladaptive remodeling of the carotid artery parameters among 
women in the recovery MetS group suggests that MetS risk factor modification measures could 
have a significant and positive impact on subclinical cardiovascular disease risk. 
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8.2 INTRODUCTION 
 
Metabolic syndrome (MetS) is a risk factor for cardiovascular disease (CVD), especially 
stroke [210], that incorporates central obesity, dyslipidemia, elevated blood pressure (BP), and 
elevated plasma glucose.  While the relationship between MetS and the risk of stroke is poorly 
understood, it has been hypothesized that changes in structural and functional arterial properties  
play a role in this relationship given the varying effects of  MetS status changes [211, 212]. 
 
Arterial remodeling (AR) refers to changes in structural and functional properties of 
arteries over time, and it occurs largely in response to metabolic, inflammatory and 
hemodynamic changes within the arterial environment [211, 213, 214].  AR can either be 
adaptive or maladaptive.  Maladaptive remodeling occurs with adverse changes in both 
circumferential wall stress (CWS) and circumferential wall tension (CWT) [132, 211, 215], 
whereas adaptive remodeling occurs without changes in CWS and CWT [216].  Maladaptive 
remodeling has been shown to be associated with the risk of stroke, as evidenced by higher mean 
carotid CWT among patients who have had stroke [132, 212]. 
 
Several epidemiological studies have linked the presence of MetS to carotid artery 
remodeling in diverse study populations in terms of age as well as CVD risk factors [170, 211, 
212, 217-219]. Compared to  participants without MetS, young adults with MetS have been 
observed with a higher mean IMT [220], and an accelerated IMT progression over time [92, 
170].  MetS has also been shown to be associated with carotid remodeling in non-diabetic 
individuals [211], middle-aged women [218], and older adults  independent of CVD risk factors 
[221].   Significant changes in CVD risk factors are reported to have a corresponding and 
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favorable change in markers of subclinical atherosclerosis.  Change in MetS status, however, is 
posited to have varying effects on the vasculature based on the handful of published articles.  In 
longitudinal studies examining  the effect of MetS status change on the vasculature, specifically 
the carotid artery, recovery from MetS was found to be significantly associated with a reduction 
in carotid artery properties such as lumen diameter (LD), IMT and adventitial diameter(AD) 
among young adults [212, 219] compared to those without a change in their metabolic status.  To 
date, however, carotid artery properties of only young adults have been studied in relation to 
change in MetS status and thus carotid artery properties  in relation to change in MetS status in 
midlife and elderly women and men are unknown.  
 
Adding to our understanding of MetS status change on the vasculature among midlife 
women is important because  prevalence of the MetS increases during menopause transition  
independent of aging and other known CVD risk factors [79].  We sought to assess the effects of 
MetS status changes on carotid artery parameters changes over time. In addition, we examined 
changes in circumferential wall tension and circumferential wall stress to characterize the pattern 
of remodeling over time.  Given these goals, we examined changes in carotid artery structural 
and functional parameters in relation to changes in MetS status and its components in the Study 
of Women’s Across the Nation (SWAN) Heart Study. 
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8.3 METHODS 
 
8.3.1 Study Population 
 
The study sample included women enrolled in the Study of Women’s Health Across the 
Nation (SWAN).  SWAN is a multiethnic, community-based, longitudinal cohort of the natural 
history of 3302 women enrolled at 7 sites throughout the United States (Boston, Massachusetts; 
Chicago, Illinois; Detroit, Michigan; Los Angeles, California; Oakland, California; Newark, 
New Jersey; and Pittsburgh, Pennsylvania).  The cohort at baseline was composed of White, 
Black, Chinese, Japanese and Hispanic women, aged 42 to 52 years, who had an intact uterus 
and at least one ovary, had at least one menstrual period in the preceding 3 months, had not used 
sex steroid hormone therapy in the preceding 3 months and were not pregnant. 
 
 The data for current study are from the SWAN Heart study, an ancillary study 
designed to examine natural history of subclinical atherosclerosis during the menopausal 
transition from two sites.  The Pittsburgh and Chicago sites both recruited and followed Black 
and White women.  At the baseline (N =425) and follow-up (N=343) participants were recruited 
and followed.   The final sample size consisted of 252 participants had data on both baseline and 
follow-up visits, and data to ascertain MetS status of the participants.   Baseline and follow-up 
visits occurred between 2001 and 2004.  The mean follow-up was approximately 2 years.  The 
institutional review board at each site approved the protocol and all women provided written 
informed consent.  
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8.3.2 Covariates Measures 
  
At the baseline and follow-up visits, interviewer-administered questionnaires were used 
to assess medication use, lifestyle characteristics, menopausal status, and physical measures. 
Fasting blood samples were drawn for assessments of cardiovascular risk factors and included 
triglycerides, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-
cholesterol and fasting glucose.  Fasting blood samples were analyzed at the Medical Research 
Laboratories (Lexington, KY).   EDTA-treated plasma was used to analyze lipids.  Isolation of 
high-density lipoprotein – cholesterol (HDL-C) (mg/dL) was done with heparin-2 M manganese 
chloride, and low density lipoprotein (LDL-c) (mg/dL) was estimated with the Friedewald 
equation [222].  
 
8.3.3 International Diabetes Federation (IDF) metabolic syndrome definition 
 
The criterion for the determination of the MetS using the IDF definition is sex-specific 
and we only describe the components as they pertain to women.  Within the IDF definition for 
MetS, central obesity is required to be a component of the criteria, plus two or more of the other 
factors.  The components of IDF are as follows: waist circumference (WC) ≥80 cm for those 
self-identified as White or Black; triglycerides ≥150 mg/dL; systolic blood pressure (SBP) ≥130 
mmHg or diastolic blood pressure (DBP)  ≥85 mmHg or on antihypertensive medication; HDL-c 
< 50 mg/dL; fasting glucose ≥ 100 mg/dL [176].  
 
Participants were classified as having MetS or not at baseline and follow-up visits.  
Participants were then assigned into one of the following 4 groups of MetS status based on two 
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assessments: never (no MetS at both baseline and follow-up), incident (MetS at follow-up but 
not at baseline), recovery (MetS at baseline but not at follow-up) and persistent (MetS at both 
visits).   
 
8.3.4 Subclinical Measures 
 
At baseline and follow-up, carotid intima-media thickness (IMT) and adventitial diameter 
were assessed using B-mode ultrasound (Pittsburgh site: Toshiba American Medical Systems, 
Tustin, CA; and Chicago site: Hewlett Packard, Andover, MA) by centrally trained and certified 
sonographers.  Right and left carotid arteries were scanned to obtain a total of eight images: near 
and far wall of the common carotid (1 cm proximal to the bulb), far wall of the common bulb 
(starting from point where the common carotid walls are no longer parallel and ending at the 
flow divider), and far wall of the internal carotid artery (distal 1 cm from the flow divider).  IMT 
was measured by using the Artery Measurement Systems (AMS), a semi-automated edge 
detection software [177], by tracing the lumen-intima interface and the media-adventitia 
interface across a 1-cm segment.  A total of 140 measures for each segment were generated, and 
the mean value of the averaged readings at all 8 locations was used.  For AD, the distance from 
the adventitial-medial interface on the near wall to the medial-adventitial interface on the far wall 
at end-diastole was measured for both right and left common carotid artery.  Lumen diameter 
(LD) was measured directly, and defined as the distance from the intima-lumen interface of the 
near wall to the lumen-intima interface of the far wall.  Mean circumferential wall tension 
(CWT) and circumferential wall stress (CWS) were calculated according to Laplace’s law [194] 
and mean CWT (kPa) = MAP (LD/2) and CWS (kPa) = mean CWT/IMT [189], where MAP is 
the mean arterial pressure.  MAP was approximated as [(2* diastolic blood pressure) + systolic 
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blood pressure]/3. To assess the reproducibility of subclinical measures, 20 scans were 
performed to examine the inter-reader reproducibility of the measures, with an intra-class 
correlation of 0.98 and 0.99 for carotid IMT and AD, respectively [202]. 
 
8.3.5 Statistical Analyses 
 
 Baseline demographic and cardiovascular disease risk factor characteristics were 
compared by the four categories of change in MetS status (never, incident, recovery and 
persistent groups) using the chi-square test for categorical variables, and either t-test or Wilcoxon 
tests for continuous variables depending on normality.   
 
 Generalized estimating equations (GEE) were used to assess differences in carotid artery 
parameters at baseline and at follow up, and their changes over time between the four MetS 
status groups.  MetS groups were included in these analyses as dummy variables and differences 
were tested relative to the reference group (never) and the differences in changes were tested by 
MetS group x time interaction terms.  The individual components that comprise MetS were 
assessed in their continuous form in relation to carotid artery parameters at the baseline, follow 
up and their changes over time.   All analyses were adjusted for age, site, education, smoking, 
LDL-c, cholesterol lowering medication, and menopausal status.  For the regression models, the 
associations between MetS status changes and carotid artery properties were reported in Beta 
coefficients and 95% confidence intervals. All analyses were conducted using SAS version 9.3 
and STATA version 12.   
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8.4 RESULTS 
 
 Baseline demographic and clinical characteristics of the study participants by the four 
MetS groups are shown in Table 8-1.  The participants in the MetS recovery group were slightly 
older at baseline compared to the other three groups.  In aggregate, the majority of participants 
were either premenopausal or peri-menopausal, reported receiving at least some college 
education and 67.5% of the study participants were White.  From baseline to follow up, mean 
body mass index (BMI) increased in the incident group, and decreased in the recovery group.  As 
expected, there were changes in individual components that comprised the MetS in relation to 
the four MetS groups, particularly among the women in the incident and recovery groups. 
Among the incident group, mean SBP, DPB, WC and triglycerides were higher at the follow-up 
visit compared to baseline, whereas mean HDL-c values declined.   The women in the recovery 
group experienced declines in mean SBP, DBP, WC and triglyceride values from baseline to 
follow-up and HDL-c levels increased slightly during follow-up.    From baseline to follow-up, 
mean SBP, DBP and HDL-c decreased slightly and mean WC increased in both the persistent 
and the never MetS groups. 
 
 Significant differences in carotid artery properties and changes in MetS status from 
baseline to follow-up visits were found.  The overall MetS status changes were associated with 
subclinical measures in each period.  At baseline and follow-up, the women in the persistent 
MetS group had larger mean IMT (0.76±0.12), and the recovery MetS group had larger mean 
AD (7.2±0.07), LD (5.6 ± 0.67), CSA (15.2±2.4), CWT (34.1±4.4), and CWS(53.3±7.8) as 
compared to other MetS groups.  At baseline, participants with persistent MetS had significantly 
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higher levels of mean IMT, CSA and CWT, but not of AD, LD and CWS compared to 
participants who never developed MetS (Table 8-1).   
 
During the follow-up, the persistent MetS group experienced a steeper increase in carotid 
IMT compared to those who never developed MetS (0.02 versus 0.012 mm/y) (Table 8-2 and 
Figure 8-1).   The recovery women showed a negative rate of change on LD (-0.1 versus 0.0 
mm/y), whereas other MetS categories did not differ in comparison to the reference group.  The 
women in the recovery MetS experienced substantial increases in CSA (0.45 versus 0.35 mm/y).  
CWT increased in both the incident (0.45 versus -0.3 kPa/y) and persistent (0.05 versus -0.3 
kPa/y) MetS groups and decreased in the recovery MetS group (-1.55 versus -0.3 kPa/y) as 
compared to the never group. 
 
 The associations between the four MetS status groups and changes in carotid artery 
parameters are shown in Table 8-3.  At baseline, higher levels of AD, IMT, LD, CSA, CWT and 
CWS were significantly related to SBP and waist circumference. At the follow-up visit, higher 
levels of AD, LD, CSA, CWT and CWS were significantly and positively associated with SBP 
and waist circumference.  Carotid IMT at follow-up was significantly associated with SBP, but 
not with waist circumference.  Finally, positive changes in SBP were positively associated with 
changes in LD, CWT and CWS from baseline to follow-up. 
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8.5 DISCUSSION 
 
The current study assessed the effect of longitudinal MetS status changes on carotid 
artery remodeling in an established cohort of midlife women participating in SWAN heart study.  
Among women with persistent MetS, we found significant increases in mean AD, IMT, LD and 
CWT over the follow-up period and also higher mean baseline values of IMT, CSA and CWT as 
compared to those who never developed MetS (Figure 8-1). Moreover, women with persistent 
MetS experienced increases in IMT and CSA in the course of follow-up, along with an increase 
in CWT.  Women in Recovery MetS group experienced a decrease in LD and CWT, and a 
significant decline in CWS over the follow-up period.  Higher systolic blood pressure and larger 
waist circumference were significant and consistent determinants of adverse carotid artery 
remodeling in our current study.  
In the present study, we observed varying effects of MetS status changes on the carotid 
artery remodeling in midlife women.  The arterial remodeling among women with persistent 
MetS was considered maladaptive because we found increases in IMT, AD and CSA, along with 
an increase in CWT.  This finding suggests that among midlife women without CVD, persistent 
MetS is associated with the thickening of the carotid artery wall independent of confounding risk 
factors such as age, smoking, education, menopausal status, LDL-c and race.  While the carotid 
artery properties of women in the recovery MetS group profile improved in relation to the factors 
related to the nature and pattern of the remodeling, slight increases were observed in mean AD 
and IMT,  suggesting an adaptive vascular response [216].   Similar observations had been made 
in The Cardiovascular Risk in Young Finns Study [219] , and the Amsterdam Growth and Health 
Longitudinal Study [212].   In lieu of these findings, it has been suggested that there is the likely 
reversibility of a pathobiological process in young adults, which if not caught in time, could 
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progress into overt cardiovascular or cerebrovascular disease, such as a stroke or myocardial 
infarction. 
 In our study, participants in the recovery MetS group were observed to have significantly 
different carotid artery properties as compared to those who never developed MetS.   This 
finding shows that favorable changes in MetS are likely to have a corresponding favorable effect 
on the carotid artery.  Although artery remodeling occurred in all four MetS groups over time, 
those in the recovery group were not considered maladaptive because there was a reduction in 
mean transmural pressure in the carotid artery.  Lifestyle and medical therapy interventions 
targeted to alter or treat or manage CVD risk factors, such as hypertension, diabetes mellitus, 
dyslipidemia and obesity, have been shown to slow or delay the progression of atherosclerosis or 
in some instances regression of atherosclerosis has been reported [92, 219, 223-225].   
Atherosclerosis is initiated through oxidized LDL particles and  macrophages activation, which 
leads to the formation of foam cells [143, 226].  The foam cells  trigger fatty streak formation in 
atherosclerosis [143, 227].  On the other hand, modified LDL particles are also able to clear the 
artery wall of foam cell lesions through the liver via HDL-c  [228].  In the Young Finn cohort 
study, a 6-year change in HDL-c was inversely associated with carotid IMT progression.  In light 
of these findings, Koskinen et al hypothesized that reversing  foam cell lesions could explain the 
favorable changes in carotid artery properties or measures among participants whose MetS status 
improved from baseline to follow-up [219]. 
In evaluating the individual components of MetS, systolic blood pressure was 
significantly associated with carotid artery remodeling.   Increases in LD, CWT and CWS were 
positively associated with SBP even after adjusting for covariates such as age, smoking status, 
LDL-c, education and menopausal status.  This finding is a potential indication of the effects of 
109 
 
pulsatile components of blood pressure on arterial remodeling.  Another  competing explanation 
for  this observation is that transmural pressure exerts excess force on load-bearing features of  
arterial wall, such as elastin and collagen, which in turn leads to changes and fractures in the 
extracellular matrix and eventually results in arterial enlargements [229].  Larger waist 
circumference was associated with AD, LD, CWT and CWS in both the baseline and the follow-
up period alone, but in the longitudinal models, WC was not significantly related to measures of 
arterial remodeling.  These observations suggest that blood pressure and abdominal obesity are 
likely the two MetS criteria most strongly related with adverse effects on carotid arterial 
properties.  Our findings, in these contexts, are in agreement with what others have been reported 
in the literature [211, 217, 218, 221].   In adults, Ferreira et al made a similar observation 
regarding the effects of blood pressure and abdominal obesity on carotid remodeling [212], 
however, they used a revised MetS definition completely different the criteria recommended by 
IDF. 
Our study has strengths and limitations. The follow-up period was approximately 2 years, 
which might not be long enough to truly evaluate the effect of MetS and its individual 
components on carotid artery remodeling.  The sample size of the four MetS groups was 
relatively small, especially in the incident, persistent and recovery categories, but our sample size 
was comparable to the few studies that have investigated MetS status changes on carotid artery 
remodeling. Women in recovery MetS group experienced reduction in LD, CWT and CWS but 
given the sample size in that category much emphasis could not be placed on it.   Moreover, 
SWAN Heart study was not designed to examine the very question we sought to understand in 
this study.  Mean arterial pressure measures were estimated versus directly measuring them in 
the arteries.  Brachial artery blood pressure was used to derive CWT and CWS in place of    
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blood pressure measurements taken directly in the carotid arteries, therefore there is the 
likelihood of underestimation or overestimation of these measures in our analyses.  Our study 
has a number of strengths. This is the first study to have investigated MetS and potential changes 
and carotid artery parameters in midlife women over time.  The mean carotid artery IMT across 
carotid segments was used because it captures early atherosclerosis better among young women 
than simply using means in other segments alone.  The artery measurement system was used to 
directly measure lumen diameter in this study compared to deriving it based on other measures 
of the carotid artery. 
 In conclusion, midlife women with persistent MetS over the course of 2-years of follow-
up were more likely to experience carotid artery remodeling compared to those who never 
developed MetS.  Furthermore, the type of arterial remodeling among those with persistent MetS 
appeared to be maladaptive, which might put these women at higher risk factor for 
cardiovascular disease, and in particular stroke.  The reversibility of maladaptive remodeling of 
the carotid artery parameters among women in the recovery MetS group suggests that MetS risk 
factor modification measures could have a significant and positive impact on subclinical 
cardiovascular disease risk. 
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8.6 TABLES AND FIGURES 
Table 8-1 Characteristic of Study population at Baseline and follow-up by Metabolic Syndrome Status Changes 
Characteristics Time 
Metabolic Syndrome Status 
Never(n=170) Incident(n=21) Recovery(n=16) Persistent(n=45) 
Age (years) Baseline 50.5±2.6 49.4±2.5 52.1±2.9 50.5±3.0 
Follow-up 52.5±2.6 51.5±2.5 54.3±2.9 52.9±3.0 
Ethnicity n (%) 
Black 50(29.4) 7(33.3) 7(43.7) 18(40.0) 
White 120(70.6) 14(66.7) 9(56.3) 27(60.0) 
Menopausal status n (%) 
Post-menopausal 46(30.5) 4(19.0) 7(53.8) 14(28.6) 
Late /Early Premenopausal 105(69.5) 17(80.8) 6(46.1) 31(68.9) 
Education n (%) 
 High School 29(17.1) 3(14.3) 2(12.5) 8(17.8) 
Some College 88(51.8) 11(52.4) 10(62.5) 23(51.1) 
Post Grad. School 53(31.2) 7(33.3) 4(25.0) 14(31.1) 
Individual components of MetS 
Systolic Blood Pressure (mm Hg) Baseline 114.1±14.9 119.1±11.7 128.9±20.3 125.4±18.7 
Follow-up 113.3±14.6 121.2±15.7 121.5±12.5 124.0±15.7 
Diastolic Blood Pressure (mm Hg) Baseline 73.9±9.5 75.3±8.9 81.3±10.8 77.8±9.3 
Follow-up 72.4±8.5 78.2±9.3 75.6±9.9 77.3±11.7 
Waist Circumference (cm) Baseline 84.9±13.3 92.3±12.0 94.8±11.1 101.7±13.0 
Follow-up 85.4±13.1 95.1±12.7 93.5±10.9 103.1±13.5 
HDL cholesterol Baseline 61.6±13.0 49.8±7.5 51.4±11.4 44.4±8.8 
Follow-up 61.7±13.3 43.8±6.0 52.8±9.1 44.3±7.9 
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Characteristics Time 
Metabolic Syndrome Status 
Never(n=170) Incident(n=21) Recovery(n=16) Persistent(n=45) 
Triglycerides Baseline 97.0±32.0 131.2±61.9 159.7±65.9 209.0±175.4 
Follow-up 101.8±46.2 158.0±47.2 117.9±38.1 201.7±106.2 
Other risk factors 
 Body mass index (kg/m2) Baseline 27.7±5.9 29.8±5.1 30.4±4.1 34.1±6.4 
Follow-up 27.9±5.7 30.9±5.3 29.3±3.6 34.2±6.0 
Current smoking, n (%) Baseline 20 (12.2) 1 (5) 3 (20) 5 (11.4) 
Follow-up 20 (12.9) 1 (5) 3 (18.8) 6 (13.6) 
LDL cholesterol Baseline 117.3±32.2 120.6±37.5 137.9±40.8 128.6±37.6 
Follow-up 122.6±30.5 126.6±33.7 128.6±32.1 132.5±38.6 
Blood pressure lowering medication, n 
(%) 
Baseline 20 (11.8) 2 (9.5) 6 (37.5) 16 (35.6) 
Follow-up 24 (14) 4 (19) 7 (43.7) 19 (42.2) 
Cholesterol lowering medication, n (%) Baseline 6 (3.5) 0 (0.0) 2 (12.5) 5 (11.1) 
Follow-up 13 (7.7) 2 (9.5) 5 (31.3) 11 (24.4) 
Carotid  Artery parameters 
Carotid IMT(mm) Baseline 0.67±0.09 0.66±0.09 0.70±0.07 0.73±0.11 
Follow-up 0.71±0.09 0.68±0.09 0.75±0.07 0.76±0.12 
Adventitial diameter(mm) Baseline 6.6±0.53 6.5±0.72 7.2±0.7 6.8±0.52 
Follow-up 6.7±0.54 6.6±0.7 7.2±0.7 6.9±0.54 
Lumen diameter (mm) Baseline 5.3±0.44 5.2±0.56 5.8±0.51 5.4±0.50 
Follow-up 5.3±0.45 5.2±0.51 5.6±0.67 5.4±0.53 
Wall cross-sectional area (mm2) Baseline 12.6±2.2 12.3±2.5 14.3±2.2 14.1±2.5 
Follow-up 13.3±2.3 12.7±2.9 15.2±2.4 14.7±2.6 
Circumferential wall tension(kPa) Baseline 30.9±5.4 31.2±5.2 37.2±5.5 33.6±2.1 
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Table 8-1 Continued
Characteristics Time 
Metabolic Syndrome Status 
Never(n=170) Incident(n=21) Recovery(n=16) Persistent(n=45) 
Follow-up 30.3±5.1 32.1±5.8 34.1±4.4 33.7±5.8 
Circumferential wall stress(kPa) Baseline 46.6±8.6 47.4±7.4 53.3±7.8 46.7±9.2 
Follow-up 43.3±8.3 47.3±7.6 45.8±8.5 45.6±10.3 
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Table 8-1 Continued
Table 8-2 Comparison of Carotid Artery measures across categories of Changes in Metabolic Syndrome Status 
Baseline Follow-up 2-year changes 
β 95% CI β 95% CI β 95% CI Dependent variable Changes in MetS 
status 
 Adventitial Diameter (mm) Incident 0.048 -0.216, 0.313 0.050 -0.202, 0.303 0.004 -0.128, 0.135 
Recovery 0.404  -0.064, 0.744 0.313 -0.008, 0.634 -0.036 -0.202, 0.131 
Persistent 0.174 -0.018, 0.367 0.247 0.066, 0.429** 0.054 -0.041, 0.148 
Carotid IMT (mm) Incident 0.0023 -0.036, 0.041 -0.017 -0.059, 0.025 -0.022 -0.051, 0.008 
Recovery 0.0149 -0.035, 0.065 0.0458 -0.007, 0.099 0.023 -0.015, 0.061 
Persistent 0.0485 0.019, 0.077** 0.026 0.010, 0.070** -0.016 -0.038, 0.005 
Lumen Diameter (mm) Incident -0.034 -0.242, 0.174 0.177 -0.196, 0.247 0.048 -0.083, 0.179 
Recovery 0.311 0.047, 0.575* 0.352 -0.105, 0.459 -0.092 -0.256, 0.072 
Persistent 0.133 -0.021, 0.287 0.193  0.034, 0.353* 0.083 -0.013, 0.180 
Wall cross-sectional area (mm2) Incident -0.018 -1.03, 0.99 -0.274 -1.33, 0.785 -0.238 -0.891, 0.413 
Recovery 1.02 -0.269, 2.31 1.39 0.041, 2.74* 0.309 -0.506, 1.12 
Persistent 1.24 0.485, 1.99** 1.29 0.533, 2.05** -0.024 -0.505, 0.456 
Circumferential wall tension (kPa) Incident 0.87 -1.53, 3.18 2.34 0.10, 4.58* 1.27 -0.66, 3.05 
Recovery 4.8 1.89, 8.28** 1.90 -0.95, 4.74 -2.08 -0.52, 3.06 
Persistent 2.54 0.85, 7.67** 3.08 1.47, 4.68** 0.44 -0.88, 1.76 
Circumferential wall stress (kPa) Incident 0.99 -2.85, 4.84 4.23 0.36, 4.64 2.84 -0.49, 6.17 
Recovery 5.7 0.85, 10.6* -0.03 -4.95, 4.89 -4.17 -8.3, -0.009* 
Persistent 0.72 -2.14, 3.57 2.25 -0.53, 5.03 1.63 -0.82, 4.08 
Adjusted for age, smoking, education, race, LDL-c, cholesterol lowering medication, menopausal status as well as changes in the adjusted covariates in the 2-year 
change model;* *p <0.001; *p <0.05 
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Table 8-3  The associations between changes in each metabolic syndrome characteristic and changes in Carotid Artery parameters 
 
  Dependent Variable 
Independent Variable Time AD IMT LD CSA CWT CWS 
Systolic blood pressure Baseline 0.295*** 0.342*** 0.213** 0.369** 0.801*** 0.586*** 
 Follow-up 0.312*** 0.354*** 0.200** 0.381*** 0.759*** 0.491*** 
 2 year change 0.107 -0.059 0.141* 0.016 0.767*** 0.582*** 
Waist circumference Baseline 0.297*** 0.239*** 0.276*** 0.291 0.267*** 0.118 
 Follow-up 0.262*** 0.110 0.253*** 0.192*** 0.239*** 0.148 
 2 year change 0.007 -0.053 0.037 -0.049 0.103 0.106 
HDL cholesterol Baseline -0.027 -0.099 -0.0129 -0.058 -0.019 0.038 
 Follow-up -0.093 -0.061 -0.050 -0.072 -0.066 -0.035 
 2 year change -0.029 0.109 -0.117 0.064 -0.046 -0.117 
Triglycerides Baseline -0.019 -0.056 0.0050 -0.059 0.028 0.081 
 Follow-up 0.075 0.047 0.049 0.055 0.115 0.077 
 2 year change 0.173* -0.071 0.173** -0.005 0.161* 0.163* 
Glucose Baseline 0.102 0.093 0.095 0.107 0.129 0.066 
 Follow-up 0.061 0.114 0.019 0.096 0.073 0.001 
 2 year change -0.045 0.019 -0.075 -0.001 -0.039 -0.046 
Adjusted for age, smoking, education, LDL-c, cholesterol lowering medication, menopausal status as well as changes in the adjusted covariates in the 2-year 
change model * **p <0.0001** p <0.001 *p <0.05 
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Figure 8-1 Changes in carotid artery parameters by changes in metabolic syndrome status 
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 9.0   GENERAL DISCUSSION 
 
9.1 SUMMARY OF FINDINGS 
 
This dissertation sought to examine the MetS and its association with subclinical 
atherosclerosis, carotid artery remodeling and its related risk factors, as well as the longitudinal 
effect of MetS status changes on carotid artery remodeling in midlife women.  The summary of 
the findings for chapter 6, 7 and 8 are presented below. 
In chapter 6, the MetS, via all definitions, was significantly associated with measures of 
subclinical atherosclerosis.  The WHO definition was more strongly associated with carotid IMT 
and carotid plaque presence compared to either the NCEP-ATP III or the IDF definitions.   The 
MetS components most strongly and consistently associated with carotid IMT and plaque were 
higher blood pressure and greater fasting glucose across all definitions considered in the current 
study. 
In chapter 7, the MetS was significantly associated with maladaptive remodeling of the 
common carotid artery as indicated by greater mean adventitial diameter, lumen diameter and 
carotid IMT.  Moreover, an outward pattern of remodeling was observed as evidenced by greater 
mean circumferential wall tension and circumferential wall stress in women with MetS.  Our 
findings also indicated that the associations between MetS and carotid artery remodeling are 
independent of inflammatory, hemodynamic, and metabolic risk factors.  Finally, we observed 
differential maladaptive remodeling patterns of the common carotid artery with MetS status by 
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race/ethnicity.  Specifically, Black and Hispanic women experienced more extreme remodeling 
of the common carotid artery with MetS than their White counterparts. 
In chapter 8, among women with persistent MetS, we found significant increases in mean 
AD, IMT, LD and CWT over the follow-up period and also higher mean baseline values of IMT, 
CSA and CWT as compared to those who never developed MetS.   Moreover, women with 
persistent MetS experienced increases in IMT and CSA in the course of follow-up, along with an 
increase in CWT.  Recovery MetS women experienced a decrease in LD and CWT, and a 
significant decline in CWS over the follow-up period.  Higher systolic blood pressure and larger 
waist circumference were significant and consistent determinants of adverse carotid artery 
remodeling in our current study. 
 
9.2 STRENGTHS AND LIMITATIONS 
 
In light of the significant findings of the dissertation, strengths and limitations of the 
manuscript must be enumerated.  The strengths and limitations of chapter 6, 7 and 8 are 
presented below. 
In chapter 6, the sample consisted of community - dwelling women in whom subclinical 
atherosclerosis burden was assessed by centrally trained vascular sonographers with no 
knowledge of participants’ CVD risk factors.  The study sample was multi-racial and multi-
ethnic and comprised of White, Black, Chinese and Hispanic women.  To our knowledge, this 
was the first study to assess three commonly used MetS definitions and their individual 
components in relation to subclinical atherosclerosis in a racially/ethnically diverse group of 
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middle-aged women.  However, this was a cross-sectional study; therefore the findings must be 
interpreted with caution. 
In chapter 7, this is the first study to assess carotid artery remodeling in a multi-ethnic 
cohort focused on examining the association between MetS and carotid remodeling in non-
diabetic older middle-aged women.  As a cross-sectional study, inferences regarding causality 
must be made with caution.  There was paucity of data in Hispanic ethnicity therefore the 
importance of comparisons made in this study must be carefully interpreted. No three 
dimensional images of the carotid artery image were made, therefore vascular measurements 
such as CWT and CWS might have either underestimated or overestimated the association 
between MetS and carotid artery remodeling.    
In chapter 8, the follow-up period was approximately 2 years, which might not be long 
enough to truly assess the effect of MetS and its individual components on carotid artery 
remodeling.  The size of the four MetS groups was relatively small, especially the incident, 
persistent and recovery categories, but our sample size was comparable to the few studies that 
have investigated MetS status changes on their effects on carotid artery remodeling.  Moreover, 
SWAN Heart study was not designed to examine the very question we sought to examine.  This 
is the first study to have investigated MetS and potential changes and carotid artery parameters in 
midlife women over time.  The mean carotid artery IMT across carotid segments was used 
because it captures early atherosclerosis better among young women than simply using means in 
other segments alone.   
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9.3 PUBLIC HEALTH SIGNIFICANCE 
 
Subclinical atherosclerosis is thought to precede overt clinical cardiovascular events, 
such as stroke in high-risk populations.  The presence of MetS is a strong predictor of incident 
CVD events.   MetS is linked to subclinical atherosclerosis and maladaptive remodeling of the 
carotid artery.  Lifestyle modifications including, a healthy diet, physical activity, cessation of 
smoking and weight control/loss, and pharmacological intervention targeting specific MetS 
components can be initiated to mitigate the effects of the MetS, and maybe reduce the risk for 
subclinical atherosclerosis progression and CVD events.  This dissertation has provided evidence 
that MetS may promote vascular remodeling among midlife women.  This finding is very 
important because targeting MetS via its components may reverse or prevent vascular 
remodeling, and subsequently reduce risk for the development of cardiovascular events in 
women. 
 
9.4 FUTURE RESEARCH  
 
Findings from this dissertation have shown the importance of metabolic syndrome and 
development of subclinical atherosclerosis, which is a precursor to CVD events.  Data show that 
women on average develop CVD ten to fifteen years later in life than men, and this is suggested 
to be due largely to  menopause[230].  With this background, metabolic syndrome and its 
components must be prospectively studied to understand how they affect the development and 
progression of atherosclerosis in midlife.  Understanding metabolic syndrome and its 
components and how they are related to the development of subclinical atherosclerosis in women 
10 years prior to the menopause transition can potentially help to prevent CVD among women. 
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 9.5 CONCLUSION 
 
In summary, the presence of MetS using three definitions was significantly associated 
with greater burden of subclinical atherosclerosis in midlife women.  MetS is also associated 
with maladaptive remodeling of the common carotid artery in midlife women independent of 
select measure of inflammatory, metabolic and hemodynamic risk factors.  Midlife women with 
persistent MetS status over a 2-year period were significantly associated with maladaptive 
remodeling of the carotid artery after adjusting for potential confounders.   These findings 
suggest that targeting and preventing MetS and its components may potentially reduce 
subclinical CVD in midlife women. 
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